Search

Your search keyword '"Gabelle A"' showing total 1,471 results
Start Over Author "Gabelle A"
1,471 results on '"Gabelle A"'

401. Clinical relevance of brain atrophy subtypes categorization in memory clinics.

Author

Planche, Vincent, Bouteloup, Vincent, Mangin, Jean‐François, Dubois, Bruno, Delrieu, Julien, Pasquier, Florence, Blanc, Frédéric, Paquet, Claire, Hanon, Olivier, Gabelle, Audrey, Ceccaldi, Matthieu, Annweiler, Cédric, Krolak‐Salmon, Pierre, Habert, Marie‐Odile, Fischer, Clara, Chupin, Marie, Béjot, Yannick, Godefroy, Olivier, Wallon, David, and Sauvée, Mathilde

Abstract

Introduction: The clinical relevance of brain atrophy subtypes categorization in non‐demented persons without a priori knowledge regarding their amyloid status or clinical presentation is unknown. Methods: A total of 2083 outpatients with either subjective cognitive complaint or mild cognitive impairment at study entry were followed during 4 years (MEMENTO cohort). Atrophy subtypes were defined using baseline magnetic resonance imaging (MRI) and previously described algorithms. Results: Typical/diffuse atrophy was associated with faster cognitive decline and the highest risk of developing dementia and Alzheimer's disease (AD) over time, both in the whole analytic sample and in amyloid‐positive participants. Hippocampal‐sparing and limbic‐predominant atrophy were also associated with incident dementia, with faster cognitive decline in the limbic predominant atrophy group. Lewy body dementia was more frequent in the hippocampal‐sparing and minimal/no atrophy groups. Discussion: Atrophy subtypes categorization predicted different subsequent patterns of cognitive decline and rates of conversion to distinct etiologies of dementia in persons attending memory clinics. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

402. Five‐Year Lower Extremity Function is Associated with White Matter Abnormality in Older Adults.

Author

He, Lingxiao, Souto Barreto, Philipe, Giudici, Kelly Virecoulon, Gabelle, Audrey, Perus, Lisa, Mangin, Jean‐François, Rolland, Yves, and Vellas, Bruno

Subjects
HEALTH of older people, DIFFUSION tensor imaging, WHITE matter (Nerve tissue), FUNCTIONAL status, LEG
Abstract

Objective: To explore associations between changes of lower extremity function (LEF) parameters over a 5‐year period and diffusion tensor imaging (DTI) parameters of white matter tracts among community‐dwelling older adults. Design: A secondary analysis on image and physical function data collected from the Multidomain Alzheimer's Preventive Trial (MAPT). Participants: 208 older adults (aged 75 ± 4 years, with spontaneous memory complaint or limited instrumental daily living activity or slow gait speed, 60% female) of the MAPT‐magnetic resonance imaging (MRI) ancillary study. The time interval between a participant's enrolment and MRI scan was on average 110 ± 97 days. Measurements: Forty‐eight white matter tracts (WMTs) were measured. LEF parameters (measured after the MRI scan) were assessed as the short physical performance battery (SPPB) score, gait speed, and chair stands time over a 5‐year period. Mixed‐effects models were performed to explore the associations between baseline DTI values and the progression of LEF parameters. Bonferroni correction was applied for multiple comparison correction. Results: The progression of LEF was associated with 35 baseline DTI parameters from 24 WMTs. Higher baseline DTI parameter values were related to more decreases in SPPB score and gait speed, and greater increases in chair stands time. Bilateral uncinate fasciculus was associated with all LEF parameters. Other WMTs in cingulum, cerebral and cerebellar peduncle, internal capsule, and corpus callosum also showed close connections with LEF changes. Conclusions: Our findings show that DTI parameters of some WMTs are associated with the 5‐year decline in LEF, suggesting that alterations in WMT integrity (evaluated by DTI parameters) might be used to explore potential causes of impaired mobility in older adults when no clear explanations can be found. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

404. Association of Long-Term Diet Quality with Hippocampal Volume : Longitudinal Cohort Study

Author

Akbaraly, Tasmine, Sexton, Claire, Zsoldos, Eniko, Mahmood, Abda, Filippini, Nicola, Kerleau, Clarisse, Verdier, Jean-Michel, Virtanen, Marianna, Gabelle, Audrey, Ebmeier, Klaus, Kivimäki, Mika, Akbaraly, Tasmine, Sexton, Claire, Zsoldos, Eniko, Mahmood, Abda, Filippini, Nicola, Kerleau, Clarisse, Verdier, Jean-Michel, Virtanen, Marianna, Gabelle, Audrey, Ebmeier, Klaus, and Kivimäki, Mika

Abstract

Background: Diet quality is associated with brain aging outcomes. However, few studies have explored in humans the brain structures potentially affected by long-term diet quality. We examined whether cumulative average of the Alternative Healthy Eating Index 2010 (AHEI-2010) score during adult life (an 11-year exposure period) is associated with hippocampal volume. Methods: Analyses were based on data from 459 participants of the Whitehall II imaging sub-study (mean age [standard deviation] (SD) = 59.6 [5.3] years in 2002-2004, 19.2% women). Multimodal magnetic resonance imaging examination was performed at the end of follow-up (2015-2016). Structural images were acquired using a high-resolution 3-dimensional T1-weighted sequence and processed with Functional Magnetic Resonance Imaging of the Brain Software Library (FSL) tools. An automated model-based segmentation and registration tool was applied to extract hippocampal volumes. Results: Higher AHEI-2010 cumulative average score (reflecting long-term healthy diet quality) was associated with a larger total hippocampal volume. For each 1 SD (SD = 8.7 points) increment in AHEI-2010 score, an increase of 92.5 mm3 (standard error = 42.0 mm3) in total hippocampal volume was observed. This association was independent of sociodemographic factors, smoking habits, physical activity, cardiometabolic health factors, cognitive impairment, and depressive symptoms, and was more pronounced in the left hippocampus than in the right hippocampus. Of the AHEI-2010 components, no or light alcohol consumption was independently associated with larger hippocampal volume. Conclusions: Higher long-term AHEI-2010 scores were associated with larger hippocampal volume. Accounting for the importance of hippocampal structures in several neuropsychiatric diseases, our findings reaffirm the need to consider adherence to healthy dietary recommendation in multi-interventional programs to promote healthy brain aging.

Published
2018
Full Text
View/download PDF

405. Towards a routine application of Top-Down approaches for label-free discovery workflows

Author

Schmit, P.O., Vialaret, J., Wessels, H.J., Gool, A.J. van, Lehmann, S., Gabelle, A., Wood, J., Bern, M., Paape, R., Suckau, D., Kruppa, G., Hirtz, C., Schmit, P.O., Vialaret, J., Wessels, H.J., Gool, A.J. van, Lehmann, S., Gabelle, A., Wood, J., Bern, M., Paape, R., Suckau, D., Kruppa, G., and Hirtz, C.

Abstract

Item does not contain fulltext

Published
2018

406. Author Correction: Pathogenic p62/ SQSTM1 mutations impair energy metabolism through limitation of mitochondrial substrates

Author

Bartolomé Robledo, Fernando [0000-0001-9322-8933], Esteras, Noemí [0000-0002-7938-6131], Martín-Requero, Ángeles [0000-0002-3416-9440], Boutoleau-Bretonnière, Claire [0000-0001-9051-6315], Ber, Isabelle Le [0000-0002-2508-5181], Honda, Tadashi [0000-0003-0746-9453], Dinkova-Kostova, Albena T. [0000-0003-0316-9859], Hardy, John A. [0000-0002-3122-0423], Bartolomé Robledo, Fernando, Esteras, Noemí, Martín-Requero, Ángeles, Boutoleau-Bretonnière, Claire, Vercelletto, Martine, Gabelle, Audrey, Ber, Isabelle Le, Honda, Tadashi, Dinkova-Kostova, Albena T., Hardy, John A., Carro, Eva, Abramov, Andrey Yurevich, Bartolomé Robledo, Fernando [0000-0001-9322-8933], Esteras, Noemí [0000-0002-7938-6131], Martín-Requero, Ángeles [0000-0002-3416-9440], Boutoleau-Bretonnière, Claire [0000-0001-9051-6315], Ber, Isabelle Le [0000-0002-2508-5181], Honda, Tadashi [0000-0003-0746-9453], Dinkova-Kostova, Albena T. [0000-0003-0316-9859], Hardy, John A. [0000-0002-3122-0423], Bartolomé Robledo, Fernando, Esteras, Noemí, Martín-Requero, Ángeles, Boutoleau-Bretonnière, Claire, Vercelletto, Martine, Gabelle, Audrey, Ber, Isabelle Le, Honda, Tadashi, Dinkova-Kostova, Albena T., Hardy, John A., Carro, Eva, and Abramov, Andrey Yurevich

Published
2018

408. Biomarker counseling, disclosure of diagnosis and follow‐up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey.

Author

Frederiksen, Kristian S., Nielsen, Thomas R., Appollonio, Ildebrando, Andersen, Birgitte Bo, Riverol, Mario, Boada, Mercè, Ceccaldi, Mathieu, Dubois, Bruno, Engelborghs, Sebastiaan, Frölich, Lutz, Hausner, Lucrezia, Gabelle, Audrey, Gabryelewicz, Tomasz, Grimmer, Timo, Hanseeuw, Bernard, Hort, Jakub, Hugon, Jacques, Jelic, Vesna, Koivisto, Anne, and Kramberger, Milica G.

Subjects
MILD cognitive impairment, ALZHEIMER'S disease, MEDICAL disclosure, COUNSELING, SUPPORT groups
Abstract

Objectives: Mild cognitive impairment (MCI) is associated with an increased risk of further cognitive decline, partly depending on demographics and biomarker status. The aim of the present study was to survey the clinical practices of physicians in terms of biomarker counseling, management, and follow‐up in European expert centers diagnosing patients with MCI. Methods: An online email survey was distributed to physicians affiliated with European Alzheimer's disease Consortium centers (Northern Europe: 10 centers; Eastern and Central Europe: 9 centers; and Southern Europe: 15 centers) with questions on attitudes toward biomarkers and biomarker counseling in MCI and dementia. This included postbiomarker counseling and the process of diagnostic disclosure of MCI, as well as treatment and follow‐up in MCI. Results: The response rate for the survey was 80.9% (34 of 42 centers) across 20 countries. A large majority of physicians had access to biomarkers and found them useful. Pre‐ and postbiomarker counseling varied across centers, as did practices for referral to support groups and advice on preventive strategies. Less than half reported discussing driving and advance care planning with patients with MCI. Conclusions: The variability in clinical practices across centers calls for better biomarker counseling and better training to improve communication skills. Future initiatives should address the importance of communicating preventive strategies and advance planning. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

409. Current status and quantitative results of the AMYPAD prognostic and natural history study: Neuroimaging / Optimal neuroimaging measures for tracking disease progression.

Author

Alves, Isadora Lopes, Gispert, Juan Domingo, Gray, Katherine R, Collij, Lyduine, Heeman, Fiona, Salvadó, Gemma, Saint‐Aubert, Laure, Payoux, Pierre, Vellas, Bruno, Boutoleau‐Bretonnière, Claire, Gabelle, Audrey, Pasquier, Florence, Dumurgier, Julien, Dubois, Bruno, Connelly, Peter, Grau‐Rivera, Oriol, Martinez‐Lage, Pablo, Boada, Mercè, Marquie, Marta, and Vandenberghe, Rik

Abstract

Background: Understanding the role of amyloid imaging in the earliest stages of Alzheimer's Disease (AD) becomes increasingly relevant for secondary prevention. In this context, the AMYPAD Prognostic and Natural History Study (PNHS) is an open‐label, prospective, multi‐centre cohort study (http://amypad.eu/) to determine the value of quantitative amyloid PET imaging in determining AD dementia risk. The study aims at enrolling 2000 non‐demented individuals from several European cohorts, with a focus on those with emerging amyloid pathology. Method: As of January 31th 2020, 438 participants have consented into AMYPAD PNHS across 15 active sites. Of those, 347 are from EPAD LCS, 9 from ALFA+ and 82 from EMIF‐AD (Figure 1). To date, 329 subjects have been scanned with [18F]flutemetamol or [18F]florbetaben, and 108 PET scans have been analyzed with IXICO's LEAP pipeline. The primary variable is the Centiloid value (CL) using the whole cerebellum as reference region. Scans were categorized as negative (CL<12); gray‐zone (1250) for amyloid burden, and associations between CL values and age, CDR and RBANS were assessed. Result: Site activation is almost complete, with two remaining sites to be activated by February 2020. In addition to current recruitment sources, two additional cohorts (FACEHBI and FPACK) have started recruitment, and at least one more is expected in February. Current AMYPAD PNHS participants have a mean age of 67.08 ± 7.71 years and 59% of them are female. The distribution of CL values ranged from ‐12.75 to 141.79 (Figure 2), and showed a positive association with age (p<0.001) as expected, with similar behavior for the each radiotracer (Figure 3). Forty‐five scans (42%) were classified as negative, 40 (37%) gray‐zone, and 23 (21%) positive. Within EPAD LCS participants, increasing amyloid burden was related to lower global scores on RBANS (ANOVA, F=3.6, p<0.05), and CDR=0.5 was most frequently observed in the gray‐zone (9.5%) and positive (12.0%) groups compared to amyloid‐negative subjects (2.1%). Conclusion: The AMYPAD Prognostic and Natural History Study is currently ongoing and a total of 17 sites will be actively recruiting by February 2020. Preliminary quantitative results indicate that the trial is effectively recruiting the intended target population. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

410. Tau hyperphosphorylation on T217 in cerebrospinal fluid is specifically associated to amyloid-β pathology

Author

Nicolas R. Barthélemy, Chihiro Sato, Audrey Gabelle, Philippe Marin, Randall J. Bateman, François Becher, and Sylvain Lehmann

Subjects
Tau hyperphosphorylation, 0303 health sciences, medicine.medical_specialty, Amyloid, Amyloid β, business.industry, Hyperphosphorylation, medicine.disease, 03 medical and health sciences, 0302 clinical medicine, Cerebrospinal fluid, Endocrinology, Internal medicine, mental disorders, medicine, Phosphorylation, Tauopathy, business, Preclinical stage, 030217 neurology & neurosurgery, 030304 developmental biology
Abstract

IntroductionModification of CSF tau phosphorylation in AD remains controversial since total-tau and phospho-tau levels measured by immunoassays are highly correlated.MethodsStoichiometry of phosphorylation of CSF tau was monitored on five sites by mass spectrometry. We compared 50 participants with AD at mild to moderate stages, others tauopathies and controls then confirmed our results in a cohort of 86 participants cognitively normal or with mild cognitive impairment and stratified according to amyloid-β status.ResultsChanges in tau phosphorylation rates were observed in AD participants but not in other tauopathies. T181 appeared slightly hyperphosphorylated in AD. In comparison, T217 phosphorylation, was considerably modified. We demonstrated T217 hyperphosphorylation occurred systematically in amyloid positive participants even at preclinical stage (AUC 0.999). T217 phosphorylation change specificity overpasses other phosphorylated tau sites investigated in this study, but also CSF total-tau and p-tau levels.DiscussionCSF T217 hyperphosphorylation defines a specific tauopathy status concomitant with ß-amyloidosis.

Published
2017

411. Excessive Sleepiness and Longer Nighttime in Bed Increase the Risk of Cognitive Decline in Frail Elderly Subjects: The MAPT-Sleep Study

Author

Audrey Gabelle, Laure-Anne Gutierrez, Isabelle Jaussent, Sophie Navucet, Caroline Grasselli, Karim Bennys, Cécilia Marelli, Renaud David, Sandrine Andrieu, Claudine Berr, Bruno Vellas, Yves Dauvilliers, Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Département de neurologie [Montpellier], Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Gui de Chauliac [Montpellier]-Université de Montpellier (UM), Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, Hôpital Gui de Chauliac [Montpellier]-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Université de Montpellier (UM), and Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)

Subjects
frailty and cognitive impairment, 0301 basic medicine, Gerontology, Aging, Cognitive Neuroscience, Population, Excessive daytime sleepiness, lcsh:RC321-571, 03 medical and health sciences, 0302 clinical medicine, Insomnia, medicine, Sleep study, sleep, Cognitive decline, education, lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry, Original Research, education.field_of_study, excessive daytime sleepiness, [SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontology, Epworth Sleepiness Scale, amyloid, [SDV.NEU.SC]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Cognitive Sciences, Cognition, cognitive decline, medicine.disease, 030104 developmental biology, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Alzheimer disease, medicine.symptom, Alzheimer's disease, Psychology, 030217 neurology & neurosurgery, Neuroscience
Abstract

International audience; Objective: To identify self-reported sleep-wake disturbances that increase the risk of cognitive decline over 1-year follow-up in frail participants.Background: Risk factors for cognitive impairment need to be better identified especially at earliest stages of the pathogenesis. Sleep-wake disturbances may be critical factors to consider and were thus being assessed in this at-risk population for cognitive decline.Methods: Frail elderly participants aged >=70 years were selected from a subsample of the Multi-domain Alzheimer Preventive Trial (MAPT) for a sleep assessment (MAPT-sleep study) at 18-month follow-up (M18). Sleep-wake disturbances were evaluated using a clinical interview (duration of daytime and nighttime sleep, time in bed, number of naps, and presence of clinically-defined sleep disorders) and numerous validated questionnaires [Epworth Sleepiness Scale for excessive daytime sleepiness (EDS), Insomnia Severity Scale and Berlin Questionnaire]. Cognitive decline was defined as a difference between the MMSE and cognitive composite scores at M24 and M36 that was ranked in the lowest decile. Multivariate logistic regression models adjusted for several potential confounding factors were performed.Results: Among the 479 frail participants, 63 developed MMSE-cognitive decline and 50 cognitive composite score decrease between M24 and M36. Subjects with EDS had an increased risk of MMSE decline (OR = 2.46; 95% CI [1.28; 4.71],p= 0.007). A longer time spent in bed during night was associated with cognitive composite score decline (OR = 1.32 [1.03; 1.71],p= 0.03). These associations persisted when controlling for potential confounders. Patients with MMSE score decline and EDS had more naps, clinically-defined REM-sleep Behavior Disorder, fatigue and insomnia symptoms, while patients with cognitive composite score decline with longer time in bed had increased 24-h total sleep time duration but with higher wake time after onset.Conclusions: The risk of cognitive decline is higher in frailty subjects with EDS and longer nighttime in bed. Early detection of sleep-wake disturbances might help identifying frail subjects at risk of cognitive decline to further propose sleep health strategies to prevent cognitive impairment. http://www.clinicaltrials.gov NCT00672685; Date of registration May, 2nd 2008.

Published
2017

412. Association between serum hepcidin level and restless legs syndrome

Author

Yves, Dauvilliers, Sofiene, Chenini, Jérôme, Vialaret, Constance, Delaby, Lily, Guiraud, Audrey, Gabelle, Regis, Lopez, Christophe, Hirtz, Isabelle, Jaussent, and Sylvain, Lehmann

Subjects
Adult, Aged, 80 and over, Male, Hepcidins, Tandem Mass Spectrometry, Polysomnography, Restless Legs Syndrome, Humans, Female, Middle Aged, Statistics, Nonparametric, Aged, Chromatography, Liquid
Abstract

To better understand the role of iron homeostasis dysregulation in restless legs syndrome, we compared serum hepcidin and ferritin levels in drug-free patients with primary restless legs syndrome and healthy controls and studied the relationship between hepcidin level and restless legs syndrome severity.One hundred and eight drug-free patients with primary restless legs syndrome (65 women; median age, 61.5 years) and 45 controls (28 women; median age, 53.9 years) were enrolled. Inclusion criteria were: normal ferritin level (50 ng/mL) and absence of iron disorders, chronic renal or liver failure, and inflammatory or neurological diseases. Each subject underwent a thorough clinical examination and a polysomnography assessment. Serum hepcidin-25 was quantified using a validated mass spectrometry method. Restless legs syndrome severity was evaluated according to the International Restless Legs Syndrome Study Group.Despite no group difference between normal ferritin levels and demographic features, serum hepcidin level and hepcidin/ferritin ratio were higher in patients than in controls. Hepcidin level and hepcidin/ferritin ratio, but not ferritin level, were positively correlated with periodic leg movements during sleep and wakefulness in the whole sample. Hepcidin level seem to be associated with restless legs syndrome severity in a complex U-shaped relationship, without relationship with age at restless legs syndrome onset, positive family history, sleep and depressive symptoms, genetic background, and polysomnographic measurements. No relationship was found between ferritin level and restless legs syndrome severity.In drug-free patients with primary restless legs syndrome, hepcidin level is higher than in controls and may be associated with restless legs syndrome clinical severity. This result emphasizes the complex peripheral iron metabolism deregulation in restless legs syndrome, opening potential perspectives for a personalized approach with a hepcidin antagonist. © 2018 International Parkinson and Movement Disorder Society.

Published
2017

413. [O1–13–05]: IS THE PROSPECTIVE ASSOCIATION BETWEEN DOMAIN‐SPECIFIC COGNITIVE IMPAIRMENT AND INCIDENT DEMENTIA MODIFIED BY EDUCATION? THE MEMENTO COHORT

Author

Frédéric Blanc, Jacques Hugon, Bruno Dubois, Serge Belliard, Mathieu Ceccaldi, Sophie Auriacombe, Olivier Hanon, Olivier Rouaud, Geneviève Chêne, Pierre Jean Ousset, Catherine Thomas-Antérion, Renaud David, Florence Pasquier, Alexandra Foubert-Samier, Carole Dufouil, Pierre Krolak Salmon, and Audrey Gabelle

Subjects
Epidemiology, business.industry, Health Policy, medicine.disease, Domain (software engineering), Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Cohort, Medicine, Dementia, Neurology (clinical), Geriatrics and Gerontology, business, Cognitive impairment, Association (psychology), Clinical psychology
Published
2017

414. [P1–240]: CLINICAL IMPACT OF CEREBROSPINAL FLUID BIOMARKERS IN MILD COGNITIVE IMPAIRMENT DIAGNOSIS

Author

Jacques Hugon, Florence Pasquier, Julien Dumurgier, François Mouton-Liger, Eloi Magnin, Anne-Cécile Troussière, Emmanuel Cognat, Emmanuelle Duron, Claire Paquet, Audrey Gabelle, Philippe Robert, Didier Hannequin, and David Wallon

Subjects
medicine.medical_specialty, Epidemiology, business.industry, Health Policy, Gastroenterology, 030227 psychiatry, 03 medical and health sciences, Psychiatry and Mental health, Cellular and Molecular Neuroscience, 0302 clinical medicine, Cerebrospinal fluid, Developmental Neuroscience, Internal medicine, medicine, Neurology (clinical), Geriatrics and Gerontology, business, Cognitive impairment, 030217 neurology & neurosurgery
Published
2017

415. [O2–10–05]: SHORT‐TERM PREDICTION OF CONVERSION FROM MILD COGNITIVE IMPAIRMENT TO DEMENTIA IN PATIENTS IN THE MEMENTO COHORT, 2011–2016

Author

Renaud David, Jean-François Mangin, Emilie Beaufils, Clélia Favary, Florence Pasquier, Jacques Hugon, Vincent Bouteloup, Bruno Vellas, Frédéric Blanc, Marie Chupin, Bruno Dubois, Carole Dufouil, Olivier Hanon, Pierre Krolak Salmon, Olivier Rouaud, Mathieu Ceccaldi, Geneviève Chêne, Audrey Gabelle, and François Tison

Subjects
Pediatrics, medicine.medical_specialty, Epidemiology, business.industry, Health Policy, medicine.disease, Term (time), Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Cohort, medicine, Dementia, In patient, Neurology (clinical), Geriatrics and Gerontology, business, Cognitive impairment
Published
2017

416. [P1–273]: QUANTIFICATION OF HEPCIDIN‐25 IN HUMAN CEREBROSPINAL FLUID: TECHNICAL FEASIBILITY AND BIOLOGICAL RELEVANCE IN NEURODEGENERATIVE DISEASES

Author

Audrey Gabelle, Constance Delaby, Vincent Delatour, Amandine Moulinier, Alexia Picas, Pauline Bros, Sylvain Lehmann, Christophe Hirtz, Christian Geny, Jérôme Vialaret, Yves Dauvilliers, and Cyndi Catteau

Subjects
biology, Epidemiology, business.industry, Health Policy, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Technical feasibility, Cerebrospinal fluid, Developmental Neuroscience, Hepcidin, biology.protein, Medicine, Relevance (information retrieval), Neurology (clinical), Geriatrics and Gerontology, business, Neuroscience
Published
2017

417. [P2–258]: HIGHLY SPECIFIC CSF TAU HYPERPHOSPHORYLATION ON T217 OCCURS SIMULTANEOUSLY WITH AMYLOIDOSIS

Author

Randall J. Bateman, Nicolas R. Barthélemy, Audrey Gabelle, Chihiro Sato, and Sylvain Lehmann

Subjects
Gerontology, Tau hyperphosphorylation, Pathology, medicine.medical_specialty, Epidemiology, business.industry, Health Policy, Amyloidosis, medicine.disease, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Medicine, Neurology (clinical), Geriatrics and Gerontology, business
Published
2017

418. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial

Author

Sandrine Andrieu, Sophie Guyonnet, Nicola Coley, Christelle Cantet, Marc Bonnefoy, Serge Bordes, Lawrence Bories, Marie-Noëlle Cufi, Thierry Dantoine, Jean-François Dartigues, Françoise Desclaux, Audrey Gabelle, Yannick Gasnier, Alain Pesce, Kristel Sudres, Jacques Touchon, Philippe Robert, Olivier Rouaud, Philippe Legrand, Pierre Payoux, Jean-Paul Caubere, Michael Weiner, Isabelle Carrié, Pierre-Jean Ousset, Bruno Vellas, Lauréane Brigitte, Catherine Faisant, Françoise Lala, Julien Delrieu, Hélène Villars, Emeline Combrouze, Carole Badufle, Audrey Zueras, Christophe Morin, Gabor Abellan Van Kan, Charlotte Dupuy, Yves Rolland, Céline Caillaud, Bertrand Fougère, Sherry Willis, Sylvie Belleville, Brigitte Gilbert, Francine Fontaine, Isabelle Marcet, Fleur Delva, Alexandra Foubert, Sandrine Cerda, Marie Noëlle-Cuffi, Corinne Costes, Patrick Manckoundia, Valérie Quipourt, Sophie Marilier, Evelyne Franon, Marie-Laure Pader, Marie-France Basset, Bruno Lapoujade, Valérie Faure, Michael Li, Yung Tong, Christine Malick-Loiseau, Evelyne Cazaban-Campistron, Colette Blatge, Cécile Laubarie-Mouret, Isabelle Saulnier, Jean-Pierre Clément, Marie-Agnès Picat, Laurence Bernard-Bourzeix, Stéphanie Willebois, Iléana Désormais, Noëlle Cardinaud, Pierre Livet, Pascale Rebaudet, Claire Gédéon, Catherine Burdet, Flavien Terracol, Stéphanie Roth, Sylvie Chaillou, Sandrine Louchart, Nicolas Lebrun, Nadège Barro-Belaygues, Karim Bennys, Aurélia Romano, Lynda Touati, Cécilia Marelli, Cécile Pays, Franck Le Duff, Claire Gervais, Sébastien Gonfrier, Danièle Begorre, Christian Carpuat, Khaled Khales, Jean-François Lefebvre, Samira Misbah El Idrissi, Pierre Skolil, Jean-Pierre Salles, Carole Dufouil, Stéphane Lehéricy, Marie Chupin, Jean-François Mangin, Ali Bouhayia, Michèle Allard, Frédéric Ricolfi, Dominique Dubois, Marie Paule, Bonceour Martel, François Cotton, Alain Bonafé, Stéphane Chanalet, Françoise Hugon, Fabrice Bonneville, Christophe Cognard, François Chollet, Thierry Voisin, Sophie Peiffer, Anne Hitzel, Michel Zanca, Jacques Monteil, Jacques Darcourt, Laurent Molinier, Hélène Derumeaux, Nadège Costa, Christian Vincent, Bertrand Perret, Claire Vinel, Pascale Olivier-Abbal, Institut National de la Santé et de la Recherche Médicale (INSERM), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, CHU Toulouse [Toulouse], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hopital de Tarbes, Service de Gériatrie (CHARLES FOIX - Gériatrie), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Hopital de castres, CHU Limoges, CHU Bordeaux [Bordeaux], Hopital Lavaur, Département de neurologie [Montpellier], Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Gui de Chauliac [Montpellier]-Université de Montpellier (UM), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Hôpital Princesse Grace [Monaco], Centre hospitalier de Montauban, Neuropsychiatrie : recherche épidémiologique et clinique, Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Cognition Behaviour Technology (CobTek), Université Nice Sophia Antipolis (... - 2019) (UNS), Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Institut Claude Pompidou [Nice] (ICP - Nice)-Centre Hospitalier Universitaire de Nice (CHU Nice), Centre Mémoire Ressources et Recherche [Dijon] (CMRR Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Institut National de la Recherche Agronomique (INRA), Department of Nuclear Medicine, CHU de Toulouse (CHU), Centre de Recherche Pierre Fabre, University of California [San Francisco] (UCSF), University of California, Service d'Etudes du Comportement des Matériaux de Conditionnement (SECM), Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Interactions, transferts, ruptures artistiques et culturels - EA 6301 (InTRu), Université de Tours, École de sages-femmes Baudelocque (ESF Baudelocque), Université Paris Descartes - Paris 5 (UPD5), Gérontopôle, Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Genetique medicale, Centre hospitalier universitaire de Poitiers (CHU Poitiers), Epidémiologie et Biostatistique [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de médecine gériatrique (CHU de Dijon - Centre gériatrique de Champmaillot - EHPAD), Cabinet médical [Dijon], Cabinet médical, Handicap, Activité, Vieillissement, Autonomie, Environnement (HAVAE), Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Sciences et Société, Historicité, Éducation et Pratiques (EA S2HEP), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Centre de Mémoire de Ressources et de Recherches [Limoges] (CMRR Limoges), CHU Limoges-CH Esquirol [Limoges] (CH Esquirol), Service de Chirurgie Thoracique et Vasculaire - Médecine vasculaire [CHU Limoges], Centre d'EPistémologie et d'ERgologie Comparatives - UMR 7304 (CEPERC), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Centre de droit privé fondamental (CDPF), Université de Strasbourg (UNISTRA)-L'europe en mutation : histoire, droit, économie et identités culturelles, Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche de l'Institut du Cerveau et de la Moelle épinière (CRICM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC), Service de Neurologie, Université Montpellier 1 (UM1)-Hôpital Guy de Chauliac-Centre Mémoire Ressources Recherche Languedoc - Roussillon, Laboratoire d'Informatique Médicale (LIM), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), The Smithsonian Museum Conservation Institute, Chercheur indépendant, Centre Léon Bérard [Lyon], Neuroépidémiologie, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [APHP], Institut de Neurosciences cognitives et intégratives d'Aquitaine (INCIA), Université Bordeaux Segalen - Bordeaux 2-Université Sciences et Technologies - Bordeaux 1-SFR Bordeaux Neurosciences-Centre National de la Recherche Scientifique (CNRS), Service de neuroradiologie, imagerie des urgences [CHU de Dijon], Urgence et post-urgence psychiatrique, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Hôpital Pasteur [Nice] (CHU), Imagerie cérébrale et handicaps neurologiques, Institut des sciences du cerveau de Toulouse. (ISCT), Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut des Neurosciences de Montpellier - Déficits sensoriels et moteurs (INM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre de recherche sur l'Inflammation (CRI (UMR_S_1149 / ERL_8252 / U1149)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Diderot - Paris 7 (UPD7), Service de Médecine Nucléaire [Toulouse], CHU Toulouse [Toulouse]-Hôpital Rangueil, Hôpital Gui de Chauliac, Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Transporteurs en Imagerie et Radiothérapie en Oncologie (TIRO - UMR E4320), Service Hospitalier Frédéric Joliot (SHFJ), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-UMR E4320 (TIRO-MATOs), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Nice Sophia Antipolis (... - 2019) (UNS), Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Nice Sophia Antipolis (... - 2019) (UNS), Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA), Service de l'Information Médicale, CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], Centre de Physiopathologie Toulouse Purpan ex IFR 30 et IFR 150 (CPTP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université de Toulouse (UT), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), CHU Charles Foix [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Gui de Chauliac [CHU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université de Montpellier (UM), Centre hospitalier de Montauban (CH Montauban), Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre Hospitalier Universitaire de Nice (CHU Nice)-Institut Claude Pompidou [Nice] (ICP - Nice)-Université Côte d'Azur (UCA), Service de Médecine Nucléaire - Rangueil [CHU Toulouse], Pôle imagerie médicale [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre de Recherche Pierre Fabre (Centre de R&D Pierre Fabre), PIERRE FABRE, University of California [San Francisco] (UC San Francisco), University of California (UC), Université de Tours (UT), Université Paris Descartes - École de sages-femmes Baudelocque (UPD ESF Baudelocque), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Centre d'EPistémologie et d'ERgologie Comparatives (CEPERC), Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Montpellier 1 (UM1)-Hôpital Gui de Chauliac [CHU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Centre Mémoire Ressources Recherche Languedoc - Roussillon, Université de Rennes (UR), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Université Bordeaux Segalen - Bordeaux 2-Université Sciences et Technologies - Bordeaux 1 (UB)-SFR Bordeaux Neurosciences-Centre National de la Recherche Scientifique (CNRS), Institut des Neurosciences de Montpellier (INM), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de Médecine Nucléaire - Pierre-Paul Riquet [CHU Toulouse], Hôpital Gui de Chauliac [CHU Montpellier], Transporteurs et Imagerie, Radiothérapie en Oncologie et Mécanismes biologiques des Altérations du Tissu Osseux (TIRO-MATOs - UMR E4320), Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-UMR E4320 (TIRO-MATOs), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Côte d'Azur (UCA)-Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Côte d'Azur (UCA), Département d'Information Médicale [CHU Toulouse], Pôle Santé publique et médecine publique [CHU Toulouse], Centre de Physiopathologie Toulouse Purpan (CPTP), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), French Ministry of Health, Pierre Fabre Research Institute, Gerontopole, Exhonit Therapeutics, Avid Radiopharmaceuticals, Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute [Basel], Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées, Gérontopôle, Department of Geriatrics, Centre Hospitalier Universitaire de Toulouse, Geriatrics Department, Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), hopital de Foix, U897, Memory Research Resource Center for Alzheimer's Disease, Centre Hospitalier Universitaire de Montpellier (CHU Montpellier ), Centre Hospitalier Princesse Grace, Hopital Montauban, Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Centre Hospitalier Universitaire de Nice (CHU Nice)-Institut Claude Pompidou [Nice] (ICP - Nice), Memory Research Resource Center, Neurology Department, Laboratoire de Biochimie et Nutrition Humaine, AGROCAMPUS OUEST, Department of Nuclear Medicine, National Institute of Neurosurgery, Toulouse NeuroImaging Centre, Centre Hospitalier Universitaire de Purpan (CHU Purpan), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Toulouse [Toulouse], Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), UMR E4320 (TIRO-MATOs), Université Côte d'Azur (UCA)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Côte d'Azur (UCA)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Service Hospitalier Frédéric Joliot (SHFJ), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National de la Recherche Agronomique (INRA), Hôpital Gui de Chauliac [Montpellier]-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Université de Montpellier (UM), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hospices Civils de Lyon (HCL), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), and Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)

Subjects
Male, [SDV]Life Sciences [q-bio], Placebo-controlled study, Neuropsychological Tests, decline, law.invention, 0302 clinical medicine, Cognition, Randomized controlled trial, prevention, law, Medicine, 030212 general & internal medicine, Cognitive decline, alzheimers-disease, risk, chemistry.chemical_classification, Aged, 80 and over, education.field_of_study, Eicosapentaenoic acid, 3. Good health, Exercise Therapy, Treatment Outcome, Female, performance, Polyunsaturated fatty acid, medicine.medical_specialty, brain, Population, Placebo, 03 medical and health sciences, Double-Blind Method, Fatty Acids, Omega-3, Humans, [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, education, plasma, Aged, clinical-trials, Memory Disorders, Cognitive Behavioral Therapy, business.industry, Clinical trial, chemistry, Dietary Supplements, Physical therapy, Neurology (clinical), business, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition, gait speed, 030217 neurology & neurosurgery, dementia
Abstract

Summary Background No large trials have been done to investigate the efficacy of an intervention combining a specific compound and several lifestyle interventions compared with placebo for the prevention of cognitive decline. We tested the effect of omega 3 polyunsaturated fatty acid supplementation and a multidomain intervention (physical activity, cognitive training, and nutritional advice), alone or in combination, compared with placebo, on cognitive decline. Methods The Multidomain Alzheimer Preventive Trial was a 3-year, multicentre, randomised, placebo-controlled superiority trial with four parallel groups at 13 memory centres in France and Monaco. Participants were non-demented, aged 70 years or older, and community-dwelling, and had either relayed a spontaneous memory complaint to their physician, limitations in one instrumental activity of daily living, or slow gait speed. They were randomly assigned (1:1:1:1) to either the multidomain intervention (43 group sessions integrating cognitive training, physical activity, and nutrition, and three preventive consultations) plus omega 3 polyunsaturated fatty acids (ie, two capsules a day providing a total daily dose of 800 mg docosahexaenoic acid and 225 mg eicosapentaenoic acid), the multidomain intervention plus placebo, omega 3 polyunsaturated fatty acids alone, or placebo alone. A computer-generated randomisation procedure was used to stratify patients by centre. All participants and study staff were blinded to polyunsaturated fatty acid or placebo assignment, but were unblinded to the multidomain intervention component. Assessment of cognitive outcomes was done by independent neuropsychologists blinded to group assignment. The primary outcome was change from baseline to 36 months on a composite Z score combining four cognitive tests (free and total recall of the Free and Cued Selective Reminding test, ten Mini-Mental State Examination orientation items, Digit Symbol Substitution Test, and Category Naming Test) in the modified intention-to-treat population. The trial was registered with ClinicalTrials.gov (NCT00672685). Findings 1680 participants were enrolled and randomly allocated between May 30, 2008, and Feb 24, 2011. In the modified intention-to-treat population (n=1525), there were no significant differences in 3-year cognitive decline between any of the three intervention groups and the placebo group. Between-group differences compared with placebo were 0·093 (95% CI 0·001 to 0·184; adjusted p=0·142) for the combined intervention group, 0·079 (−0·012 to 0·170; 0·179) for the multidomain intervention plus placebo group, and 0·011 (−0·081 to 0·103; 0·812) for the omega 3 polyunsaturated fatty acids group. 146 (36%) participants in the multidomain plus polyunsaturated fatty acids group, 142 (34%) in the multidomain plus placebo group, 134 (33%) in the polyunsaturated fatty acids group, and 133 (32%) in the placebo group had at least one serious emerging adverse event. Four treatment-related deaths were recorded (two in the multidomain plus placebo group and two in the placebo group). The interventions did not raise any safety concerns and there were no differences between groups in serious or other adverse events. Interpretation The multidomain intervention and polyunsaturated fatty acids, either alone or in combination, had no significant effects on cognitive decline over 3 years in elderly people with memory complaints. An effective multidomain intervention strategy to prevent or delay cognitive impairment and the target population remain to be determined, particularly in real-world settings. Funding French Ministry of Health, Pierre Fabre Research Institute, Gerontopole, Exhonit Therapeutics, Avid Radiopharmaceuticals.

Published
2017

419. Les biomarqueurs du liquide cérébro-spinal dans la maladie d’Alzheimer : un outil de recherche utile dans la pratique clinique courante des consultations mémoire pour les cas complexes

Author

Magnin, Eloi, Dumurgier, J., Bouaziz-Amar, E., Bombois, S., Wallon, D., Gabelle, A., Lehmann, S., Blanc, F., Bousiges, O., Hannequin, D., Jung, B., Miguet-Alfonsi, C., Quillard, M., Pasquier, F., Peoc’h, K., Laplanche, J., Hugon, J., Paquet, C., Ponction Lombaire Multicentrique), groupe ePLM (étude des biomarqueurs de la, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Biomarqueurs CArdioNeuroVASCulaires (BioCANVAS), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Variabilité de réponse aux Psychotropes (VariaPsy - U1144), Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Rouen, Normandie Université (NU), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Mémoire Ressources et Recherche [Strasbourg] (CMRR Strasbourg), CHU Strasbourg, Laboratoire de Biochimie et de Biologie Moléculaire, CHU Strasbourg-Hôpital de Hautepierre [Strasbourg], Laboratoire de Pharmacologie Clinique et Toxicologie [CHRU Besancon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Laboratoire de biochimie générale [Rouen], Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Centre hospitalier universitaire de Rouen, Hôpital Beaujon, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Optimisation Thérapeutique en Neuropsychopharmacologie (VariaPsy - U1144), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Laboratoire de Pharmacologie Clinique et Toxicologie [Besancon], Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Hôpital Jean Minjoz-Université de Franche-Comté (UFC), and Hôpital Beaujon-Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)

Subjects
Biomarqueurs, Amyloid beta-Peptides, Biomedical Research, tau Proteins, Cerebro-spinal fluid, Liquide cérébro-spinal, Alzheimer's disease, Maladie d’Alzheimer, Diagnosis, Differential, Alzheimer Disease, Memory, Ponction lombaire, Lumbar puncture, Humans, Dementia, Practice Patterns, Physicians', Biomarkers, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience; The role of biomarkers in clinical research was recently highlighted in the new criteria for the diagnosis of Alzheimer's disease. Cerebro-spinal fluid (CSF) biomarkers (total Tau protein, threonine 181 phosphorylated Tau protein and amyloid Aβ1-42 peptide) are associated with cerebral neuropathological lesions observed in Alzheimer's disease (neuronal death, neurofibrillary tangle with abnormal Tau deposits and amyloid plaque). Aβ1-40 amyloid peptide dosage helps to interpret Aβ1-42 results. As suggested in the latest international criteria and the French HAS (Haute Autorité de santé) recommendations, using theses CSF biomarkers should not be systematic but sometimes could be performed to improve confidence about the diagnostic of Alzheimer's disease in young subjects or in complex clinical situations. Future biomarkers actually in development will additionally help in diagnostic process (differential diagnosis) and in prognostic evaluation of neurodegenerative diseases.

Published
2017

420. APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases

Author

Hélène-Marie Lanoiselée, Gaël Nicolas, David Wallon, Anne Rovelet-Lecrux, Morgane Lacour, Stéphane Rousseau, Anne-Claire Richard, Florence Pasquier, Adeline Rollin-Sillaire, Olivier Martinaud, Muriel Quillard-Muraine, Vincent de la Sayette, Claire Boutoleau-Bretonniere, Frédérique Etcharry-Bouyx, Valérie Chauviré, Marie Sarazin, Isabelle le Ber, Stéphane Epelbaum, Thérèse Jonveaux, Olivier Rouaud, Mathieu Ceccaldi, Olivier Félician, Olivier Godefroy, Maite Formaglio, Bernard Croisile, Sophie Auriacombe, Ludivine Chamard, Jean-Louis Vincent, Mathilde Sauvée, Cecilia Marelli-Tosi, Audrey Gabelle, Canan Ozsancak, Jérémie Pariente, Claire Paquet, Didier Hannequin, Dominique Campion, and collaborators of the CNR-MAJ project

Subjects
Medicine
Abstract

BackgroundAmyloid protein precursor (APP), presenilin-1 (PSEN1), and presenilin-2 (PSEN2) mutations cause autosomal dominant forms of early-onset Alzheimer disease (AD-EOAD). Although these genes were identified in the 1990s, variant classification remains a challenge, highlighting the need to colligate mutations from large series.Methods and findingsWe report here a novel update (2012-2016) of the genetic screening of the large AD-EOAD series ascertained across 28 French hospitals from 1993 onwards, bringing the total number of families with identified mutations to n = 170. Families were included when at least two first-degree relatives suffered from early-onset Alzheimer disease (EOAD) with an age of onset (AOO) ≤65 y in two generations. Furthermore, we also screened 129 sporadic cases of Alzheimer disease with an AOO below age 51 (44% males, mean AOO = 45 ± 2 y). APP, PSEN1, or PSEN2 mutations were identified in 53 novel AD-EOAD families. Of the 129 sporadic cases screened, 17 carried a PSEN1 mutation and 1 carried an APP duplication (13%). Parental DNA was available for 10 sporadic mutation carriers, allowing us to show that the mutation had occurred de novo in each case. Thirteen mutations (12 in PSEN1 and 1 in PSEN2) identified either in familial or in sporadic cases were previously unreported. Of the 53 mutation carriers with available cerebrospinal fluid (CSF) biomarkers, 46 (87%) had all three CSF biomarkers-total tau protein (Tau), phospho-tau protein (P-Tau), and amyloid β (Aβ)42-in abnormal ranges. No mutation carrier had the three biomarkers in normal ranges. One limitation of this study is the absence of functional assessment of the possibly and probably pathogenic variants, which should help their classification.ConclusionsOur findings suggest that a nonnegligible fraction of PSEN1 mutations occurs de novo, which is of high importance for genetic counseling, as PSEN1 mutational screening is currently performed in familial cases only. Among the 90 distinct mutations found in the whole sample of families and isolated cases, definite pathogenicity is currently established for only 77%, emphasizing the need to pursue the effort to classify variants.

Published
2017

421. App, psen1, and psen2 mutations in early-onset alzheimer disease:a genetic screening study of familial and sporadic cases

Author

Lanoiselée, Hélène-Marie, Nicolas, Gaël, Wallon, David, Rovelet-Lecrux, Anne, Lacour, Morgane, Rousseau, Stéphane, Richard, Anne-Claire, Pasquier, Florence, Rollin-Sillaire, Adeline, Martinaud, Olivier, Quillard-Muraine, Muriel, De La Sayette, Vincent, Boutoleau-Bretonnière, Claire, Etcharry-Bouyx, Frédérique, Chauviré, Valérie, Sarazin, Marie, Le Ber, Isabelle, Epelbaum, Stéphane, Jonveaux, Thérèse, Rouaud, Olivier, Ceccaldi, Mathieu, Felician, Olivier, Godefroy, Olivier, Formaglio, Maite, Croisile, Bernard, Auriacombe, Sophie, Chamard, Ludivine, Vincent, Jean-Louis, Sauvee, Mathilde, Marelli-Tosi, Cecilia, Gabelle, Audrey, Ozsancak, Canan, Pariente, Jérémie, Paquet, Claire, Hannequin, Didier, Campion, Dominique, CHU Lille, CNRS, Inserm, Université de Lille, Troubles cognitifs dégénératifs et vasculaires - U1171, Troubles cognitifs dégénératifs et vasculaires - U 1171 [TCDV], Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques (GPMCND), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de neurologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Centre Hospitalier Régional d'Orléans (CHRO), Service de génétique [Rouen], Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Département de neurologie [Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 (TCDV), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de Neurologie [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de neurologie [Nantes], Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Hôpital Guillaume-et-René-Laennec [Saint-Herblain], Service de neurologie [Angers], Université d'Angers (UA)-Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Centre Hospitalier Sainte Anne [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut du Cerveau et de la Moëlle Epinière = Brain and Spine Institute (ICM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Service de neurologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service de Neurologie générale, vasculaire et dégénérative (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Institut de Neurosciences des Systèmes (INS), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de neurologie et de neuropsychologie, Université de la Méditerranée - Aix-Marseille 2-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Service de neurologie [Amiens], CHU Amiens-Picardie, Laboratoire de Neurosciences Fonctionnelles et Pathologies - UR UPJV 4559 (LNFP), Université de Picardie Jules Verne (UPJV), Service de Neurologie [Lyon], CHU Lyon, Service de neurologie [Bordeaux], CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Pôle Psychiatrie et Neurologie [Grenoble], Centre Hospitalier Universitaire [Grenoble] (CHU), Département de neurologie [Montpellier], Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Gui de Chauliac [CHU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université de Montpellier (UM), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Biomarqueurs CArdioNeuroVASCulaires (BioCANVAS), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Lariboisière, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Département de neurologie[Lille], Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Troubles cognitifs dégénératifs et vasculaires - U 1171 (TCDV), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Gui de Chauliac [Montpellier]-Université de Montpellier (UM), CHU Toulouse [Toulouse], Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Paris Diderot - Paris 7 (UPD7)-Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Régional d'Orléans (CHR), Troubles cognitifs dégénératifs et vasculaires (U1171), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-INSERM, CHU Pitié-Salpêtrière [APHP], Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [APHP]-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon), and Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Lariboisière-Université Paris Diderot - Paris 7 (UPD7)

Subjects
Adult, Male, Heredity, Physiology, Substitution mutation, Gene Identification and Analysis, Research and Analysis Methods, Biochemistry, Nervous System, Amyloid beta-Protein Precursor, Database and Informatics Methods, Alzheimer Disease, Presenilin-2, Mental Health and Psychiatry, Presenilin-1, Genetics, Medicine and Health Sciences, Humans, Genetic Testing, Age of Onset, Cerebrospinal Fluid, Mutation databases, Biology and Life Sciences, Neurodegenerative Diseases, Genetic screens, Middle Aged, Alzheimer's disease, Body Fluids, Mutation detection, Biological Databases, Neurology, Mutation, Female, Dementia, France, Anatomy, Biomarkers, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Research Article
Abstract

Background Amyloid protein precursor (APP), presenilin-1 (PSEN1), and presenilin-2 (PSEN2) mutations cause autosomal dominant forms of early-onset Alzheimer disease (AD-EOAD). Although these genes were identified in the 1990s, variant classification remains a challenge, highlighting the need to colligate mutations from large series. Methods and findings We report here a novel update (2012–2016) of the genetic screening of the large AD-EOAD series ascertained across 28 French hospitals from 1993 onwards, bringing the total number of families with identified mutations to n = 170. Families were included when at least two first-degree relatives suffered from early-onset Alzheimer disease (EOAD) with an age of onset (AOO) ≤65 y in two generations. Furthermore, we also screened 129 sporadic cases of Alzheimer disease with an AOO below age 51 (44% males, mean AOO = 45 ± 2 y). APP, PSEN1, or PSEN2 mutations were identified in 53 novel AD-EOAD families. Of the 129 sporadic cases screened, 17 carried a PSEN1 mutation and 1 carried an APP duplication (13%). Parental DNA was available for 10 sporadic mutation carriers, allowing us to show that the mutation had occurred de novo in each case. Thirteen mutations (12 in PSEN1 and 1 in PSEN2) identified either in familial or in sporadic cases were previously unreported. Of the 53 mutation carriers with available cerebrospinal fluid (CSF) biomarkers, 46 (87%) had all three CSF biomarkers—total tau protein (Tau), phospho-tau protein (P-Tau), and amyloid β (Aβ)42—in abnormal ranges. No mutation carrier had the three biomarkers in normal ranges. One limitation of this study is the absence of functional assessment of the possibly and probably pathogenic variants, which should help their classification. Conclusions Our findings suggest that a nonnegligible fraction of PSEN1 mutations occurs de novo, which is of high importance for genetic counseling, as PSEN1 mutational screening is currently performed in familial cases only. Among the 90 distinct mutations found in the whole sample of families and isolated cases, definite pathogenicity is currently established for only 77%, emphasizing the need to pursue the effort to classify variants., In a cohort including patients with familial Alzheimer disease as well as sporadic cases of early-onset Alzheimer disease, Dominique Campion and colleagues identify previously unreported mutations to PSEN1 and PSEN2., Author summary Why was this study done? Mutations in the amyloid protein precursor (APP), presenilin-1 (PSEN1), and presenilin-2 (PSEN2) genes are a known cause of familial, early-onset Alzheimer disease (EOAD) (onset below age 65). However, in order to improve genetic counseling, it is necessary to report mutational screening from large cohorts of patients. What did the researchers do and find? In the present study, we performed sequencing of the APP, PSEN1, and PSEN2 genes in EOAD families and in 129 sporadic cases. Mutations were identified in 170 EOAD families and in 18 sporadic cases. In 10 sporadic cases, we showed that the mutation was absent in the parents, indicating that it occurred “de novo.” What do these findings mean? Sufficient evidence of pathogenicity is reached for 77% of the 90 distinct mutations identified in this sample, allowing their use in genetic counseling. Our results suggest a potential benefit to screening nonfamilial Alzheimer disease (AD) cases with onset before 50 y for APP, PSEN1, and PSEN2 mutations.

Published
2017

422. Quantification of hepcidin-25 in human cerebrospinal fluid using LC–MS/MS

Author

Pauline Bros, Jérôme Vialaret, Amandine Moulinier, Christophe Hirtz, Sylvain Lehmann, Constance Delaby, Audrey Gabelle, Vincent Delatour, Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Laboratoire commun de métrologie LNE-CNAM (LCM), and Laboratoire National de Métrologie et d'Essais [Trappes] (LNE )-Conservatoire National des Arts et Métiers [CNAM] (CNAM)

Subjects
0301 basic medicine, Iron, Clinical Biochemistry, neurological disorders, Mass spectrometry, cerebrospinal fluid, Analytical Chemistry, 03 medical and health sciences, 0302 clinical medicine, Cerebrospinal fluid, Hepcidins, LC–MS/MS, Hepcidin, Limit of Detection, Tandem Mass Spectrometry, [CHIM.ANAL]Chemical Sciences/Analytical chemistry, Lc ms ms, Biological fluids, Protein precipitation, Animals, Humans, alpha-Macroglobulins, [SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology, Solid phase extraction, General Pharmacology, Toxicology and Pharmaceutics, Chromatography, biology, Chemistry, Goats, Solid Phase Extraction, Reproducibility of Results, nutritional and metabolic diseases, General Medicine, Repeatability, MS, Medical Laboratory Technology, 030104 developmental biology, biology.protein, Linear Models, Nervous System Diseases, hepcidin-25, 030217 neurology & neurosurgery, Chromatography, Liquid
Abstract

Aim: Hepcidin, the main iron metabolism regulator, can be detected in various biological fluids. Here, we describe a quantitative method of LC–MS/MS to quantify the 25 amino acid isoform of hepcidin (hepcidin-25) in human cerebrospinal fluid (CSF). Results & methodology: Samples were prepared through protein precipitation followed by solid phase extraction (SPE) and injected into a triple-quadrupole mass spectrometer. Validation of our method included determination of LOQ (0.1 ng/ml), repeatability, intermediate precision, recovery and linearity (up to 25 ng/ml). Hepcidin-25 was subsequently quantified in 36 human CSF samples and its concentration ranged from 0.21 to 3.54 ng/ml. Conclusion: This is the first time that hepcidin-25 can be reliably quantified in human CSF. This may open interesting perspectives for the management of iron-related neurological disorders.

Published
2017

423. Orthostatic Hypotension and Risk of Incident Dementia: Results From a 12-Year Follow-Up of the Three-City Study Cohort

Author

Audrey Gabelle, Philippe Gosse, Aicha Soumare, Christophe Tzourio, Antoine Cremer, Claudine Berr, Jean-François Dartigues, Cardiologie-hypertension [Bordeaux], CHU Bordeaux, Service d’information Médicale [CHU de Bordeaux] (Pôle de Santé Publique), CHU Bordeaux [Bordeaux], Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Epidémiologie et Biostatistique [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Département de neurologie [Montpellier], Hôpital Gui de Chauliac [Montpellier]-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Université de Montpellier (UM), roussel, pascale, and Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Gui de Chauliac [Montpellier]-Université de Montpellier (UM)

Subjects
Male, medicine.medical_specialty, [SDV]Life Sciences [q-bio], Orthostatic, Standing blood pressure, 030204 cardiovascular system & hematology, Risk Assessment, orthostatic hypotension, 03 medical and health sciences, Orthostatic vital signs, Hypotension, Orthostatic, 0302 clinical medicine, Risk Factors, Internal medicine, mental disorders, Internal Medicine, medicine, Prevalence, Dementia, Humans, Geriatric Assessment, risk, Aged, Proportional Hazards Models, Intelligence Tests, business.industry, Proportional hazards model, vascular ageing community\textendashbased cohort, Confounding, blood pressure, Blood Pressure Determination, medicine.disease, [SDV] Life Sciences [q-bio], Blood pressure, Cohort, Physical therapy, Female, France, Independent Living, Hypotension, business, Risk assessment, 030217 neurology & neurosurgery, Follow-Up Studies
Abstract

International audience; Several studies indicate a potential link between orthostatic hypotension (OH) and incident dementia but without substantial evidence to date. Our objective is to study the association between OH and dementia in a cohort of elderly individuals. To do so, baseline lying and standing blood pressure measurements were taken from 7425 subjects in the Three-City study. These subjects were then followed-up for 12 years. Cox proportional hazard models, adjusted for potential confounders, were used to estimate the risk of incident dementia according to OH status. Sensitivity analysis was performed using the so-called illness-death model, a specific statistical method which takes into account competitive risk with death. OH frequency was found to be around 13%, and 760 cases of dementia were diagnosed during follow-up. We observed significant associations between the presence of OH at baseline and the occurrence of dementia during the follow-up, with an increased risk of at least 25% observed regardless of the OH threshold and the statistical method used. In conclusion, there is an association between OH and dementia. Considering that OH is a common condition and is easy to measure, OH measurements could help to identify subjects with higher risk of dementia. Moreover, reducing OH could be a step to prevent conversion to dementia.

Published
2017

424. Contribution to Alzheimer's disease risk of rare variants in TREM_2, SORL_1, and ABCA_7 in 1779 cases and 1273 controls

Author

Céline Bellenguez, Camille Charbonnier, Benjamin Grenier-Boley, Olivier Quenez, Kilan Le Guennec, Gaël Nicolas, Ganesh Chauhan, David Wallon, Stéphane Rousseau, Anne Claire Richard, Anne Boland, Guillaume Bourque, Hans Markus Munter, Robert Olaso, Vincent Meyer, Adeline Rollin-Sillaire, Florence Pasquier, Luc Letenneur, Richard Redon, Jean-François Dartigues, Christophe Tzourio, Thierry Frebourg, Mark Lathrop, Jean-François Deleuze, Didier Hannequin, Emmanuelle Genin, Philippe Amouyel, Stéphanie Debette, Jean-Charles Lambert, Dominique Campion, Olivier Martinaud, Aline Zarea, Stéphanie Bombois, Marie-Anne Mackowiak, Vincent Deramecourt, Agnès Michon, Isabelle Le Ber, Bruno Dubois, Olivier Godefroy, Frédérique Etcharry-Bouyx, Valérie Chauviré, Ludivine Chamard, Eric Berger, Eloi Magnin, Jean-Francois Dartigues, Sophie Auriacombe, François Tison, Vincent de la Sayette, Dominique Castan, Elsa Dionet, Francois Sellal, Olivier Rouaud, Christel Thauvin, Olivier Moreaud, Mathilde Sauvée, Maïté Formaglio, Hélène Mollion, Isabelle Roullet-Solignac, Alain Vighetto, Bernard Croisile, Mira Didic, Olivier Félician, Lejla Koric, Mathieu Ceccaldi, Audrey Gabelle, Cecilia Marelli, Pierre Labauge, Thérèse Jonveaux, Martine Vercelletto, Claire Boutoleau-Bretonnière, Giovanni Castelnovo, Claire Paquet, Julien Dumurgier, Jacques Hugon, Foucauld De Boisgueheneuc, Serge Belliard, Serge Bakchine, Marie Sarazin, Marie-Odile Barrellon, Bernard Laurent, Frédéric Blanc, Jérémie Pariente, Snejana Jurici, Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement - U 1167 (RID-AGE), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Excellence Laboratory LabEx DISTALZ, Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques (GPMCND), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Epidémiologie des maladies chroniques : impact des interactions gène environnement sur la santé des populations, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, Droit et Santé, INSERM Research Center for Epidemiology and Biostatistics (U897) Team Neuroepidemiology, Bordeaux, France College of Health Sciences, University of Bordeaux, Bordeaux, France, Metacohorts Consortium, Service de neurologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Centre National de Génotypage (CNG), Commissariat à l'énergie atomique et aux énergies alternatives (CEA), McGill University and Genome Quebec Innovation Centre, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 (TCDV), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Département de neurologie [Lille], Institut de Santé Publique, d'Epidémiologie et de Développement (ISPED), Institut National de la Santé et de la Recherche Médicale (Inserm)-Université de Bordeaux, Université de Bordeaux (UB), INSERM, Team Psycoépidémiologie du Vieillissement et des Maladies Chroniques - Population Health Center, Institut National de la Santé et de la Recherche Médicale (INSERM), Unité de recherche de l'institut du thorax (ITX-lab), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Epidémiologie, santé publique et développement, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR99-ISPED, Neuroépidémiologie, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Génétique, génomique fonctionnelle et biotechnologies (UMR 1078) (GGB), EFS-Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), Université de Lille, Troubles cognitifs vasculaires et dégénératifs, Université de Lille, Sciences et Technologies, Réseau International des Instituts Pasteur (RIIP), Department of Research, Centre hospitalier du Rouvray, Sotteville-lès-Rouen, France, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Département de neurologie [Montpellier], Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Gui de Chauliac [CHU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université de Montpellier (UM), CHU Amiens-Picardie, Laboratoire de Neurosciences Fonctionnelles et Pathologies - UR UPJV 4559 (LNFP), Université de Picardie Jules Verne (UPJV), CNR MAJ collaborators, ANR-10-LABX-0013,GENMED,Medical Genomics(2010), ANR-10-INBS-0009,France-Génomique,Organisation et montée en puissance d'une Infrastructure Nationale de Génomique(2010), European Project: 305299,EC:FP7:HEALTH,FP7-HEALTH-2012-INNOVATION-1,AGEDBRAINSYSBIO(2013), Troubles cognitifs dégénératifs et vasculaires - U 1171 (TCDV), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Département de neurologie[Lille], Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX), Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO)-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Gui de Chauliac [Montpellier]-Université de Montpellier (UM)

Subjects
0301 basic medicine, Male, Adult, Aging, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, SORL1, Apolipoprotein E4, Genome-wide association study, Biology, ABCA7, 03 medical and health sciences, Young Adult, Immunologic, Alzheimer Disease, Genetic variation, Receptors, medicine, 80 and over, TREM2, Humans, Genetic Predisposition to Disease, Receptors, Immunologic, Genetic Association Studies, LDL-Receptor Related Proteins, Aged, Aged, 80 and over, Genetics, Membrane Glycoproteins, Whole Genome Sequencing, General Neuroscience, Genetic Variation, Membrane Transport Proteins, Heritability, Middle Aged, Alzheimer's disease, medicine.disease, Minor allele frequency, 030104 developmental biology, biology.protein, ATP-Binding Cassette Transporters, Female, Neurology (clinical), Geriatrics and Gerontology, Developmental Biology, Genome-Wide Association Study
Abstract

International audience; We performed whole-exome and whole-genome sequencing in 927 late-onset Alzheimer disease (LOAD) cases, 852 early-onset AD (EOAD) cases, and 1273 controls from France. We assessed the evidence for gene-based association of rare variants with AD in 6 genes for which an association with such variants was previously claimed. When aggregating protein-truncating and missense-predicted damaging variants, we found exome-wide significant association between EOAD risk~and rare variants in SORL1, TREM2, and ABCA7. No exome-wide significant signal was obtained in the LOAD sample, and significance of the order of 10$^{-6}$ was observed in the whole AD group for TREM2. Our study confirms previous gene-level results for TREM2, SORL1, and ABCA7 and provides a~clearer insight into the classes of rare variants involved. Despite different effect sizes and~varying~cumulative minor allele frequencies, the rare protein-truncating and missense-predicted~damaging variants in TREM2, SORL1, and ABCA7 contribute similarly to the heritability of EOAD and explain between 1.1% and 1.5% of EOAD heritability each, compared with 9.12% for APOE $\varepsilon$4.

Published
2017

425. Editorial: Collaborative Efforts to Prevent Alzheimer's Disease

Author

Touchon, J, Rosenbaum, J, Aisen, P, Andrieu, S, Carrillo, MC, Ceccaldi, M, Dartiques, J-F, Feldman, H, Gabelle, A, Isaac, M, Fitten, LJ, Sperling, RA, Vellas, B, Tariot, P, and Weiner, M

Subjects
Clinical Trials as Topic, Nutrition and Dietetics, Nutrition & Dietetics, Alzheimer Disease, Clinical Sciences, Humans, France, United States
Published
2017

427. Additional file 1: of Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort

Author

Dufouil, Carole, Dubois, Bruno, Vellas, Bruno, Pasquier, Florence, Blanc, Frédéric, Hugon, Jacques, Hanon, Olivier, Jean-François Dartigues, Harston, Sandrine, Gabelle, Audrey, Ceccaldi, Mathieu, Beauchet, Olivier, Krolak-Salmon, Pierre, David, Renaud, Rouaud, Olivier, Godefroy, Olivier, Belin, Catherine, Rouch, Isabelle, Auguste, Nicolas, Wallon, David, Benetos, Athanase, Pariente, Jérémie, Paccalin, Marc, Moreaud, Olivier, Hommet, Caroline, Sellal, François, Boutoleau-Bretonniére, Claire, Jalenques, Isabelle, Gentric, Armelle, Vandel, Pierre, Chabha Azouani, Fillon, Ludovic, Fischer, Clara, Savarieau, Helen, Operto, Gregory, Bertin, Hugo, Chupin, Marie, Bouteloup, Vincent, Marie-Odile Habert, Jean-François Mangin, and Chêne, Geneviève

Abstract

Description of neuropsychological battery. (DOCX 29 kb)

Published
2017
Full Text
View/download PDF

428. Additional file 2: of Predicting dementia using socio-demographic characteristics and the Free and Cued Selective Reminding Test in the general population

Author

Mura, Thibault, Baramova, Marieta, Gabelle, Audrey, Artero, Sylvaine, Jean-François Dartigues, Amieva, Hélène, and Berr, Claudine

Abstract

is Table S2. presenting coefficients of logistic regression used for the construction of risk scores of Alzheimer’s dementia at 3 years and at 5 years based on age, sex, education, FCSRT scores and the interaction between socio-demographics factors and FCSRT scores. (DOCX 29 kb)

Published
2017
Full Text
View/download PDF

429. Additional file 1: of Predicting dementia using socio-demographic characteristics and the Free and Cued Selective Reminding Test in the general population

Author

Mura, Thibault, Baramova, Marieta, Gabelle, Audrey, Artero, Sylvaine, Jean-François Dartigues, Amieva, Hélène, and Berr, Claudine

Abstract

is Table S1. presenting coefficients for the linear regression analyzing the relation between FCSRT scores and age, age-squared, sex and education. (DOCX 20 kb)

Published
2017
Full Text
View/download PDF

430. Additional file 3: of Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort

Author

Dufouil, Carole, Dubois, Bruno, Vellas, Bruno, Pasquier, Florence, Blanc, Frédéric, Hugon, Jacques, Hanon, Olivier, Jean-François Dartigues, Harston, Sandrine, Gabelle, Audrey, Ceccaldi, Mathieu, Beauchet, Olivier, Krolak-Salmon, Pierre, David, Renaud, Rouaud, Olivier, Godefroy, Olivier, Belin, Catherine, Rouch, Isabelle, Auguste, Nicolas, Wallon, David, Benetos, Athanase, Pariente, Jérémie, Paccalin, Marc, Moreaud, Olivier, Hommet, Caroline, Sellal, François, Boutoleau-Bretonniére, Claire, Jalenques, Isabelle, Gentric, Armelle, Vandel, Pierre, Chabha Azouani, Fillon, Ludovic, Fischer, Clara, Savarieau, Helen, Operto, Gregory, Bertin, Hugo, Chupin, Marie, Bouteloup, Vincent, Marie-Odile Habert, Jean-François Mangin, and Chêne, Geneviève

Abstract

Memento Study Group list. (DOCX 28 kb)

Published
2017
Full Text
View/download PDF

431. Additional file 2: Table S1. of Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort

Author

Dufouil, Carole, Dubois, Bruno, Vellas, Bruno, Pasquier, Florence, Blanc, Frédéric, Hugon, Jacques, Hanon, Olivier, Jean-François Dartigues, Harston, Sandrine, Gabelle, Audrey, Ceccaldi, Mathieu, Beauchet, Olivier, Krolak-Salmon, Pierre, David, Renaud, Rouaud, Olivier, Godefroy, Olivier, Belin, Catherine, Rouch, Isabelle, Auguste, Nicolas, Wallon, David, Benetos, Athanase, Pariente, Jérémie, Paccalin, Marc, Moreaud, Olivier, Hommet, Caroline, Sellal, François, Boutoleau-Bretonniére, Claire, Jalenques, Isabelle, Gentric, Armelle, Vandel, Pierre, Chabha Azouani, Fillon, Ludovic, Fischer, Clara, Savarieau, Helen, Operto, Gregory, Bertin, Hugo, Chupin, Marie, Bouteloup, Vincent, Marie-Odile Habert, Jean-François Mangin, and Chêne, Geneviève

Abstract

Statistical significance of two-by-two cognitive categories comparisons of baseline characteristics distributions: the MEMENTO cohort. Table S2. Baseline characteristics by age group and sex: the MEMENTO cohort. Table S3. Association between baseline characteristics and number of copies of ε4 allele of APOE genotype: the MEMENTO cohort. (DOCX 47 kb)

Published
2017
Full Text
View/download PDF

432. Kinetic Energy Transfer between First Proper Orthogonal Decomposition Modes in a Mixing Tank

Author

Jean-Christophe Gabelle, Alain Liné, Jérôme Morchain, IFP Energies nouvelles (IFPEN), Laboratoire d'Ingénierie des Systèmes Biologiques et des Procédés (LISBP), Centre National de la Recherche Scientifique (CNRS)-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Recherche Agronomique (INRA), Institut National de la Recherche Agronomique (INRA)-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), and Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Intermodal kinetic energy transfer, Chemistry, General Chemical Engineering, Thermodynamics, 02 engineering and technology, General Chemistry, 021001 nanoscience & nanotechnology, Kinetic energy, Particle image velocimetry, Industrial and Manufacturing Engineering, Proper orthogonal decomposition processing, Rushton turbine, Mixing tank, Transfer (group theory), 020401 chemical engineering, Proper orthogonal decomposition, [CHIM]Chemical Sciences, 0204 chemical engineering, 0210 nano-technology
Abstract

International audience; Two-dimensional particle image velocimetry (PIV) was applied to study hydrodynamicsin a mixing tank at medium Reynolds numbers. Post-processing of PIVdata was based on proper orthogonal decomposition (POD) which enabled toreconstruct organized motion induced by impeller blades without performingangle-averaged sampling. Energy transfers between POD modes were analyzed. Inparticular, a local analysis of the modal interactions was developed in terms ofenergy transfer between the first mode, i.e., mean flow, and successive modes, i.e.,organized motion. Eventually, derivation of transfer of energy between the secondmode and fourth or fifth ones reveals a double pulsation.

Published
2017

433. Sex-specific association between neighborhood characteristics and dementia: the Three-City cohort

Author

Letellier, Noémie, Gutierrez, Laure-Anne, Carrière, Isabelle, Gabelle, Audrey, Dartigues, Jean-François, Dufouil, Carole, Helmer, Catherine, Cadot, Emmanuelle, Berr, Claudine, Berr, Claudine, Longévité et vieillissement - Histoire naturelle du déclin cognitif et du besoin de soins chez le sujet âgé - - COGICARE2007 - ANR-07-LVIE-0003 - LVIE - VALID, Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Département de neurologie [Montpellier], Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Gui de Chauliac [Montpellier]-Université de Montpellier (UM), Equipe LEHA - Inserm U1219 [Bordeaux], Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Santé Publique, d'Epidémiologie et de Développement (ISPED), Université Bordeaux Segalen - Bordeaux 2, Equipe VINTAGE - Inserm U1219 [Bordeaux], Hydrosciences Montpellier (HSM), Institut de Recherche pour le Développement (IRD)-Institut national des sciences de l'Univers (INSU - CNRS)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), This work was supported by Agence Nationale de la Recherche ANR PNR 2006 (ANR/DEDD/PNRA/PROJ/200206-01-01) and Longvie 2007 (LVIE-003-01)., and ANR-07-LVIE-0003,COGICARE,Histoire naturelle du déclin cognitif et du besoin de soins chez le sujet âgé(2007)

Subjects
Neighborhood, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Deprivation score, Socioeconomic status, Gender, Dementia, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Living environment
Abstract

International audience; INTRODUCTION:The living environment affects general health and may influence cognitive aging; however, the relationships between neighborhood characteristics and dementia are still poorly understood.METHODS:We used data from a French population-based prospective study (the Three-City cohort) that included 7016 participants aged 65 years and older with a 12-year follow-up. We used principal components analysis of neighborhood composition indicators to construct the Three-City deprivation score. To study its impact on dementia incidence, we performed survival analyses using a marginal Cox model to take into account intraneighborhood correlations. As interaction with sex was significant, analyses were stratified by sex.RESULTS:Even after controlling on individual factors, women living in deprived neighborhoods were at higher risk of dementia (hazard ratio = 1.29, 95% confidence interval 1.00-1.67) and Alzheimer's disease (hazard ratio = 1.42, 95% confidence interval 1.09-1.84). No association was found for men.DISCUSSION:Living in a deprived neighborhood is associated with higher risk of dementia in women.

Published
2017

434. Prognostic factors of second primary contralateral breast cancer in early-stage breast cancer

Author

Zheng Li, Yunfeng Zhou, Fabrice Sergent, Michel Bolla, and Isabelle Gabelle-Flandin

Subjects
Oncology, Gynecology, Cancer Research, medicine.medical_specialty, Univariate analysis, business.industry, medicine.medical_treatment, Breast surgery, Cancer, Articles, medicine.disease, Radiation therapy, breast cancer, Breast cancer, Internal medicine, parasitic diseases, contralateral breast cancer, medicine, risk factors, Hormone therapy, Family history, Stage (cooking), business, radiotherapy
Abstract

The aim of the present study was to investigate the therapeutic outcome of early-stage breast cancer (pT1aN0M0) and to identify prognostic factors for secondary primary contralateral breast cancer (CBC). A total of 85 patients with mammary carcinomas were included. All patients had undergone breast surgery and adjuvant treatment between January 2001 and December 2008 at the Central Hospital of Grenoble University (Grenoble, France). The primary end-points were disease-free survival and secondary CBC, and the potential prognostic factors were investigated. During a median follow-up of 60 months, 10 of the 85 patients presented with secondary primary cancer, of which six suffered with CBC. No patient mortalities were reported. The rates of CBC were 2.35, 3.53 and 7.06% at one, two and five years, respectively. The cumulative univariate analysis showed that microinvasion and family history are potential risk factors for newly CBC. The current study also demonstrated that secondary CBC was more likely to occur in patients with microinvasion or a family history of hte dise. In addition, the systematic treatment of secondary CBC should include hormone therapy.

Published
2014

435. Clinical measurement of Hepcidin-25 in human serum: Is quantitative mass spectrometry up to the job?

Author

Christophe Hirtz, Hervé Puy, Constance Delaby, Pauline Bros, Thibaud Lefebvre, Jérôme Vialaret, Audrey Gabelle, Sylvain Lehmann, Cellules souches normales et cancéreuses, Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre de recherche sur l'Inflammation (CRI (UMR_S_1149 / ERL_8252 / U1149)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), KARLI, Mélanie, and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 1 (UM1)-Université de Montpellier (UM)

Subjects
lcsh:QH426-470, Hepcidin, Hepcidin Iron deficiency Mass spectrometry ELISA, Mass spectrometry, Bioinformatics, Biochemistry, symbols.namesake, Detection limit, Reproducibility, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Chromatography, biology, Chemistry, Iron deficiency, Selected reaction monitoring, Repeatability, Pearson product-moment correlation coefficient, 3. Good health, lcsh:Genetics, Clinical diagnosis, biology.protein, symbols, ELISA, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience; From its discovery, hepcidin has generated many hopes in terms of diagnosis and management of a wide variety of iron-related diseases. However, in clinical use its accurate quantification remains a challenge due to the limited sensitivity, specificity or reproducibility of the techniques described. In this work, we adapted a highly specific and quantitative mass spectrometry method based on selected reaction monitoring (SRM) to measure hepcidin. Our objective was to adapt the feasibility and reproducibility of the workflow to a clinical environment. Analytical validation was performed according to ISO 15189 norms for determining the limit of detection (LOD, 2 ng/mL), limit of quantification (LOQ, 6 ng/mL), repeatability, reproducibility and linearity (up to 200 ng/mL). Using the serum of patients with various iron-related diseases we compared our SRM detection method to the well-characterized competitive ELISA (cELISA) test. The two methods were commutable (Bland–Altman plot) and we found a positive and significant correlation (r2 = 0.96, Pearson correlation coefficient p < 0.001) between both methods, although the absolute concentration determined is different from factor 5. The validation of our SRM method encourages us to propose it as an alternative approach for accurate determination of hepcidin in human samples for clinical diagnosis, follow-up and management of iron-related diseases.

Published
2014

436. O4-07-05: NIA-AA RESEARCH FRAMEWORK: APPLICATION TO THE FRENCH POPULATION BY INFERENCE FROM THE MEMENTO COHORT

Author

Cédric Annweiler, Audrey Gabelle, Olivier Hanon, Mathieu Ceccaldi, Armelle Gentric, Pierre Krolak Salmon, Catherine Belin, Marc Paccalin, Yannick Béjot, Emilie Beaufils, Pierre Jean Ousset, Florence Pasquier, Maxime Locatelli, Marie-Odile Habert, Marie Chupin, Claire Paquet, Claire Boutoleau-Bretonnière, François Tison, Vincent Bouteloup, Jean-François Mangin, David Wallon, Bruno Dubois, Carole Dufouil, Geneviève Chêne, and Frédéric Blanc

Subjects
education.field_of_study, Epidemiology, Health Policy, Population, Inference, Genealogy, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Conceptual framework, Cohort, Neurology (clinical), Geriatrics and Gerontology, Psychology, education
Published
2019

437. P4-199: PERSISTENT EFFECTS OF CONCUSSION ON ERPS IN FRENCH RUGBY PLAYERS

Author

Karim Bennys, Audrey Gabelle, Jacques Touchon, and Marc Julia

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, medicine.medical_specialty, Physical medicine and rehabilitation, Developmental Neuroscience, Epidemiology, Health Policy, Concussion, medicine, Neurology (clinical), Geriatrics and Gerontology, Psychology, medicine.disease
Published
2019

438. IRM cérébrales au cours du syndrome de Gougerot–Sjögren : résultats préliminaires et aspects anatomo-cliniques

Author

Bénédicte Maréchal, A. Le Quellec, L. Partouche, D. Etchecopar-Etchart, Audrey Gabelle, N. Menjot de Champfleur, Radjiv Goulabchand, Alexandre Thibault Jacques Maria, E. Le Bars, Sophie Navucet, Philippe Guilpain, and E. Castille

Subjects
03 medical and health sciences, 0302 clinical medicine, 05 social sciences, Gastroenterology, Internal Medicine, 0501 psychology and cognitive sciences, 030217 neurology & neurosurgery, 050105 experimental psychology
Abstract

Introduction Alors que l’anxiete et les symptomes depressifs peuvent prendre une grande place dans le syndrome de Gougerot–Sjogren (SGS), les plaintes mnesiques et attentionnelles sont frequentes mais mal objectivees. Notre travail decrit les anomalies d’imageries cerebrales chez des patients suivis pour un SGS, et recherche des associations avec les plaintes fonctionnelles et avec les resultats de tests neurocognitifs valides. Patients et methodes Au CHRU de Montpellier, entre janvier 2017 a janvier 2019, des patients suivis en medecine interne pour un SGS et rapportant des symptomes cognitifs, ont pu beneficier d’une IRM cerebrale (acquisition 3D ponderee T1 et 3D Flair) dans le cadre du soin, avec evaluation volumetriques des structures cerebrales par segmentation volumique a partir de la sequence 3DT1 MPRAGE qui a ete realisee en utilisant l’algorithme Morphobox [1] . En parallele, une evaluation cognitive a pu etre realisee par le Centre Memoire de Ressources et de Recherche (CMRR) (MMSE [Mini Mental State], Grober [test de rappel immediat et de rappel differe de 16 mots], et Epreuve du Code [WAIS] notamment). Une auto-evaluation cognitive (Questionnaire de Plainte Cognitive [QPC] et de la plainte mnesique [AEPM]) ont pu aussi etre recueillies. Les elements cliniques et biologiques de la maladie, ainsi que son activite (ESSPRI et ESSDAI) ont ete releves. Comite local d’ethique (2018_IRB-MTP_06-08). Resultats Au total, 23 patients (22 femmes et 1 homme) ont pu beneficier d’une IRM cerebrale. L’âge median etait de 53 ans [38–81] avec une duree mediane d’evolution de la maladie de 7 ans [2–38]. Le score moyen de l’ESSDAI etait de 3,30 [0–13], et celui de l’ESSPRI de 6,54 [2,97–9]. Les IRM cerebrales ont montre des hypersignaux aspecifiques de la substance blanche (classification Fazekas) pour 64,3 % des patients analyses (9/14). En comparaison aux donnees volumetriques de reference d’une population saine appariee sur l’âge et le sexe, 52,1 % (12/23) des patients avec SGS presentaient une baisse de volume de certaines structures cerebrales : LCR (18,2 %, n = 22) ; corps calleux (13,6 %, n = 22) ; substance blanche profonde (9,1 %, n = 22) ; substance grise des lobes frontaux (9,1 %, n = 22). Pour 95,7 % (22/23) de ces patients, le volume de l’hippocampe etait considere comme normal. Des analyses complementaires des donnees d’imagerie sont encore en cours. Chez ces patients, une alteration objective des fonctions cognitives [vitesse de traitement de l’information (WAIS), perception visuo-spatiale (VOSP, Figure de Rey), du langage (DO 80) et de la memoire (Grober)] a ete mise en evidence, en comparaison aux resultats obtenus pour des sujets sains apparies sur l’âge, le sexe et le niveau socioculturel (Cohorte Constances [2] ). Discussion Dans ce travail, sous reserve des analyses complementaires en cours, plus de la moitie des patients presentant un SGS presenteraient des anomalies volumetriques a l’IRM cerebrales. L’hippocampe semble ici conserver un volume normal tandis que le corps calleux, responsable de la communication inter-hemispherique, pourrait etre atrophie. Nous retrouvons par ailleurs la frequence elevee (deja decrite dans la litterature) des hypersignaux de la substance blanche (malgre l’absence de facteurs de risque cardio-vasculaires patents). Conclusion Ces resultats preliminaires suggerent l’existence de variations volumetriques des structures cerebrales chez les patients atteints de SGS et rapportant des symptomes cognitifs, ceux-la meme presentant des alterations subjectives et objectives cognitives. Ces donnees preliminaires nous incitent a completer nos travaux par l’analyse des donnees d’imagerie fonctionnelle, permettant d’integrer le fonctionnement et la connectivite cerebrale. Ceci pourrait permettre de mieux apprehender les mecanismes menant aux symptomes neurocognitifs au cours du SGS.

Published
2019

439. Dissociation de performances entre mémoire épisodique verbale et non verbale dans le trouble cognitif léger

Author

Emilie Skrobala, Olivier Hanon, Charlotte Leturcq-Jacquemont, Gabelle Audrey, Jean-Sébastien Vidal, Stéphanie Bombois, and Xavier Delbeuck

Subjects
Neurology, Neurology (clinical)
Abstract

Introduction Differentes epreuves de memoire episodique ont montre une sensibilite et specificite significative au risque de progression du trouble cognitif leger (TCL) vers la maladie d’Alzheimer. Objectifs L’objectif du travail est d’identifier l’existence de groupes de patients dont les resultats a ces epreuves de memoire episodique pourraient amener a des conclusions divergentes quant au risque de progression. Patients et Methodes Sur base des patients de la cohorte BALTAZAR (Hanon et al., 2018), nous avons constitue 4 groupes de patients TCL selon leur risque suppose de progression sur base du rappel libre/indice 16 items (verbal) et du DMS48 (non verbal) : moindre risque de progression selon les 2 epreuves (Ve−/Vi−), a risque aux 2 epreuves (Ve+/Vi + ), a risque selon l’epreuve verbale (Ve+/Vi−) ou visuelle (Ve−/Vi + ) uniquement. Ces 4 profils sont compares au niveau neuropsychologique et paraclinique. Resultats Les 4 profils sont representes : Ve−/Vi− (n = 123), Ve+/Vi+ (n = 116), Ve+/Vi− (n = 48) et Ve−/Vi+ (n = 45). Au niveau neuropsychologique, Ve+/Vi− a des scores significativement inferieurs a Ve−/Vi− a des epreuves verbales ; Ve−/Vi+ s’illustre par un score de depression superieur a Ve+/Vi+ . D’un point de vue paraclinique, Ve+/Vi−, contrairement a Ve−/Vi+, presente une atrophie hippocampique gauche et droite plus marquee, ainsi que des concentrations de proteines Tau et P-Tau plus elevees que Ve−/Vi− . Discussion Nous constatons une double dissociation des performances entre memoire episodique verbale et non verbale dans notre cohorte. En cas d’atteinte verbale predominante, une atteinte d’autres epreuves dans cette modalite est observee ainsi que des biomarqueurs de maladie d’Alzheimer plus significatifs. Un suivi evolutif des groupes est a explorer, notamment concernant la valeur predictive des profils de performances sur la conversion. Conclusion Le profil de performances a des epreuves de memoire episodique peut suggerer un risque potentiellement plus rapide de progression vers un trouble cognitif majeur en cas d’atteinte verbale.

Published
2019

440. Diabetes Mellitus and Cognition

Author

Frison, Eric, Proust-Lima, Cecile, Mangin, Jean-Francois, Habert, Marie-Odile, Bombois, Stephanie, Ousset, Pierre-Jean, Pasquier, Florence, Hanon, Olivier, Paquet, Claire, Gabelle, Audrey, Ceccaldi, Mathieu, Annweiler, Cédric, Krolak-Salmon, Pierre, Béjot, Yannick, Belin, Catherine, Wallon, David, Sauvee, Mathilde, Beaufils, Emilie, Bourdel-Marchasson, Isabelle, Jalenques, Isabelle, Chupin, Marie, Chêne, Geneviève, Dufouil, Carole, Allard, Michèle, Andrieu, Sandrine, Anthony, Pierre, Astier, Christine, Augier, Alexandre, Auguste, Nicolas, Auriacombe, Sophie, Avet, John, Bailon, Olivier, Barral, Fabrice-Guy, Barré, Jean, Barthelaix, Annick, Bayle, Catherine, Beauchet, Olivier, Belkacem, Samia, Ben Salem, Douraied, Bennys, Karim, Bera, Géraldine, Berger, Eric, Berger, Marc G, Bergouin, Emilie, Bertin-Hugault, François, Bertrand, Guillaume, Bertrand, François-Xavier, Beze, Catherine, Boilet, Valérie, Bonafé, Alain, Boudali, Yasmina, Bouhladour, Hatem, Boully, Clémence, Bouteloup, Vincent, Boutet, Claire, Bracard, Serge, Brangier, Antoine, Brillet, Pierre-Yves, Caillard, Laure, Calvas, Fabienne, Camus, Agnès, Camus, Vincent, Canaple, Sandrine, Carpentier, Antoine, Cassagnaud, Pascaline, Cattin, Françoise, Chamard, Ludivine, Chanalet, Stéphane, Chastan, Mathieu, Chauvelier, Sophie, Chauvire, Valérie, Cheriet, Samia, Clotagatide, Anthony, Cognat, Emmanuel, Cohen, Lora, Constans, Jean-Marc, Coste, Marie-Hélène, Cottier, Jean-Philippe, Cotton, François, Couret, Isabelle, Couturier, Olivier-François, Cowppli-Bony, Pascale, Cressot, Véronique, Crétin, Benjamin, Danaila, Keren, Darcourt, Jacques, Dartigues, Jean-François, Dascalita, Ana-Maria, David, Renaud, De Petigny, Xavier, De Verbizier-Lonjon, Delphine, Decousus, Marielle, Defouilloy, Isabelle, Delmaire, Christine, Delrieu, Julien, Demuyinck, Catherine, Deramecourt, Vincent, Deramond, Hervé, Desmidt, Thomas, Desruet, Marie-Dominique, Detour, Julien, Devendeville, Agnès, Didic, Mira, Doireau, Maritchu, Santos, Antonio Dos, Douillet, Patrice, Du Boisgueheneuc, Foucaud, Dubail, Delphine, Ducroq-Ducastaing, Laure, Dumurgier, Julien, Dupuy, Diane, Duron, Emmanuelle, Dygai-Cochet, Inna, Eder, Véronique, Epelbaum, Stéphane, Etcharry-Bouyx, Frédérique, Fagret, Daniel, Faisant, Catherine, Farid, Karim, Fédérico, Denis, Felician, Olivier, Fernandez, Philippe, Fosse, Pacôme, Foubert-Samier, Alexandra, Franck, Isabelle, Galitzky, Monique, Gallazzini-Crepin, Céline, Gantchev, Radka, Garbarg-Chenon, Laurence, Gautier, Guillaume, Gerardin, Emmanuel, Gervais, Claire, Getenet, Jean-Claude, Girard, Nadine, Giraud, Fabienne, Girtanner, Chantal, Gissot, Valérie, Grangeon, Caroline, Grucker, Daniel, Guedj, Eric, Gueriot, Claude, Guilhermet, Yves, Guillevin, Rémy, Haffen, Sophie, Hannequin, Didier, Harston, Sandrine, Hitzel, Anne, Hommet, Caroline, Hossein-Foucher, Claude, Hubele, Fabrice, Jacquin-Piques, Agnès, Jean, Betty, Jenn, Joanne, Joly, Laure, Jonveaux, Thérèse, Julian, Adrien, Kas, Aurélie, Kearney-Schwartz, Anna, Keles, Alice, Kelly, Antony, Keromnes, Nathalie, Koric, Lejla, Krainik, Alexandre, Kremer, Stéphane, Labourée, Florian, Lacoeuille, Franck, Lala, Francoise, Lamy, Chantal, Laplanche, Jean-Louis, Launay, Cyrille, Lehericy, Stéphane, Lehmann, Sylvain, Lenoir, Hermine, Levy, Marcel, Libercier, Stéphanie, Mackowiak-Cordoliani, Marie-Anne, Magnin, Eloi, Makaroff, Zaza, Marantidou, Athina, Marcet, Isabelle, Marelli, Cécilia, Marilier, Sophie, Martin, Idalie, Martinaud, Olivier, Martin-Hunyadi, Catherine, Medjoul, Aïcha, Merlet, Isabelle, Mestas, Danielle, Meyer, Marc-Etienne, Michel, Jean-Marc, Michon, Agnès, Migeon-Duballet, Isabelle, Mondon, Karl, Morgat, Clément, Moullart, Véronique, Moussard, Christian, Mouton, Aurélie, Namer, Izzie Jacques, Niewiadomski, Georges, Nivaggioni, Guillaume, Noblet, Marie, Nonent, Michel, Nourhashemi, Fati, Oesterle, Hélène, Orvoen, Galdric, Pallardy, Amandine, Pare, Pierre-Yves, Pasco, Anne, Payoux, Pierre, Pays, Cécile, Pellegrin, Isabelle, Perdrisot, Rémy, Perin, Bertille, Perret-Guillaume, Christine, Petyt, Grégory, Philippi, Nathalie, Pinganaud, Geneviève, Plichart, Matthieu, Pop, Gabriel, Puel, Michèle, Queneau, Mathieu, Querellou, Solène, Quillard-Muraine, Muriel, Quipourt, Valérie, Rachez, Chloé, Razzouk-Cadet, Micheline, Rigaud, Anne-Sophie, Robin-Ismer, Hélène, Rodallec, Mathieu, Rolland, Yves, Rollin-Sillaire, Adeline, Rouaud, Olivier, Roubaud, Caroline, Rouch, Isabelle, Roux, Julie, Sacco, Guillaume, Salaun, Pierre-Yves, Salmon, François, Sanchez, Alicia, Santiago-Ribeiro, Maria-Joao, Sarciron, Alain, Sastre-Hengan, Nathalie, Scheiber, Christian, Schneider, Anne-Marie, Semah, Franck, Serra, Amélie, Seux, Marie-Laure, Sordet-Guépet, Hélène, Soto, Maria Eugenia, Tafani, Mathieu, Tanguy, Jean-Yves, Taroux, Michael, Teichmann, Marc, Terrat, Catherine, Thabet, Jamila, Thalamas, Claire, Thomas-Anterion, Catherine, Troussière, Anne-Cécile, Ursu, Renata, Vera, Pierre, Vercelletto, Martine, Vercruysse, Olivier, Verger, Antoine, Viau, Philippe, Videau, Marie-Neige, Voisin, Thierry, Wagemann, Nathalie, Waissi-Sediq, Aziza, Xie, Jing, Yeni, Nathanaëlle, Zanca, Michel, and Zinszner, Jean

Published
2021
Full Text
View/download PDF

441. Primary Progressive Aphasia Associated With GRNMutations

Author

Saracino, Dario, Ferrieux, Sophie, Noguès-Lassiaille, Marie, Houot, Marion, Funkiewiez, Aurélie, Sellami, Leila, Deramecourt, Vincent, Pasquier, Florence, Couratier, Philippe, Pariente, Jérémie, Géraudie, Amandine, Epelbaum, Stéphane, Wallon, David, Hannequin, Didier, Martinaud, Olivier, Clot, Fabienne, Camuzat, Agnès, Bottani, Simona, Rinaldi, Daisy, Auriacombe, Sophie, Sarazin, Marie, Didic, Mira, Boutoleau-Bretonnière, Claire, Thauvin-Robinet, Christel, Lagarde, Julien, Roué-Jagot, Carole, Sellal, François, Gabelle, Audrey, Etcharry-Bouyx, Frédérique, Morin, Alexandre, Coppola, Cinzia, Levy, Richard, Dubois, Bruno, Brice, Alexis, Colliot, Olivier, Gorno-Tempini, Maria Luisa, Teichmann, Marc, Migliaccio, Raffaella, Le Ber, Isabelle, Belliard, Serge, Blanc, Fr´ed´eric, Ceccaldi, Mathieu, Duyckaerts, Charles, Formaglio, Ma¨ıt´e, Golfier, V´eronique, Lacomblez, Lucette, Michel, Bernard- François, Anterion, Catherine Thomas-, and Vercelletto, Martine

Published
2021
Full Text
View/download PDF

442. Current status and quantitative results of the AMYPAD prognostic and natural history study.

Author

Gispert, Juan Domingo, Alves, Isadora Lopes, Gray, Katherine R., Buckley, Christopher, Collij, Lyduine E., Heeman, Fiona, Salvadó, Gemma, García, David Vállez, Connelly, Peter, Boutoleau‐Bretonnière, Claire, Pasquier, Florence, Dumurgier, Julien, Gabelle, Audrey, Dubois, Bruno, Payoux, Pierre, Grau‐Rivera, Oriol, Martinez‐Lage, Pablo, Boada, Mercè, Marquié, Marta, and Vandenberghe, Rik

Abstract

Background: Understanding the role of amyloid imaging in the earliest stages of Alzheimer’s Disease (AD) becomes increasingly relevant for secondary prevention. In this context, the AMYPAD Prognostic and Natural History Study (PNHS) is an open‐label, prospective, multi‐centre cohort study (http://amypad.eu/) to determine the value of quantitative amyloid PET imaging in determining AD dementia risk. The study recruits from several European cohorts and aims at enrolling 2000 non‐demented individuals with a particular focus on those with emerging amyloid pathology. Method: As of January 25th, 2020, AMYPAD PNHS had 17 actively recruiting sites across Europe, and 782 non‐demented participants (>95% cognitively unimpaired) had consented to participate in the study. Of those, 448 are from EPAD LCS, 129 from EMIF‐AD Twin 60++, 111 from FACEHBI, 70 from ALFA+, 17 from FPACK, and 7 from the UCL‐2010‐412 cohort. Of the consented subjects, 334 already had an amyloid PET scan before this study. Within AMYPAD PNHS, 588 subjects have hitherto been scanned with either [18F]flutemetamol or [18F]florbetaben. Of note, 53.6% of the total number of scans have been acquired with a dual‐time window dynamic protocol. The primary outcome measure is the Centiloid value (CL) using the whole cerebellum as reference region, to enable quantitative comparability between the two tracers in the study. Also, images have been visually assessed by local raters. Of the 588 acquired scans, 296 have been quantified with IXICO’s LEAP pipeline and passed Quality Control, thus rendering valid CL values. Subjects were categorized as amyloid‐negative (CL≤12); as in a “gray‐zone” (1250) and a Gaussian Mixture Model was used to assess the population’s Centiloid distribution. Result: Based on visual assessment, 28% of the fully 296 quantified scans were visually rated as positive and 72% as negative. Quantitatively, 50% of them were categorized as negative, 33% in the gray‐zone, and 17% were positive (Figure 1). Centiloid values ranged from ‐30.3 to 154.2 (Mean±SD: 22.5±32.0 CL) (Figure 2). Conclusion: Preliminary quantitative results indicate that PNHS is being successful in recruiting a cohort mostly composed of cognitively unimpaired individuals who are enriched for early amyloid abnormalities, which is the intended target population. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

443. Assessment of Mendelian and risk-factor genes in Alzheimer disease: A prospective nationwide clinical utility study and recommendations for genetic screening

Author

Nicolas, Gaël, Zaréa, Aline, Lacour, Morgane, Quenez, Olivier, Rousseau, Stéphane, Richard, Anne-Claire, Bonnevalle, Antoine, Schramm, Catherine, Olaso, Robert, Sandron, Florian, Boland, Anne, Deleuze, Jean-François, Andriuta, Daniela, Anthony, Pierre, Auriacombe, Sophie, Balageas, Anna-Chloé, Ballan, Guillaume, Barbay, Mélanie, Béjot, Yannick, Belliard, Serge, Benaiteau, Marie, Bennys, Karim, Bombois, Stéphanie, Boutoleau-Bretonnière, Claire, Branger, Pierre, Carlier, Jasmine, Cartz-Piver, Leslie, Cassagnaud, Pascaline, Ceccaldi, Mathieu-Pierre, Chauviré, Valérie, Chen, Yaohua, Cogez, Julien, Cognat, Emmanuel, Contegal-Callier, Fabienne, Corneille, Léa, Couratier, Philippe, Cretin, Benjamin, Crinquette, Charlotte, Dauriat, Benjamin, Dautricourt, Sophie, de la Sayette, Vincent, de Liège, Astrid, Deffond, Didier, Demurger, Florence, Deramecourt, Vincent, Derollez, Céline, Dionet, Elsa, Doco Fenzy, Martine, Dumurgier, Julien, Dutray, Anaïs, Etcharry-Bouyx, Frédérique, Formaglio, Maïté, Gabelle, Audrey, Gainche-Salmon, Anne, Godefroy, Olivier, Graber, Mathilde, Gregoire, Chloé, Grimaldi, Stephan, Gueniat, Julien, Gueriot, Claude, Guillet-Pichon, Virginie, Haffen, Sophie, Hanta, Cezara-Roxana, Hardy, Clémence, Hautecloque, Geoffroy, Heitz, Camille, Hourregue, Claire, Jonveaux, Thérèse, Jurici, Snejana, Koric, Lejla, Krolak-Salmon, Pierre, Lagarde, Julien, Lanoiselée, Hélène-Marie, Laurens, Brice, Le Ber, Isabelle, Le Guyader, Gwenaël, Leblanc, Amélie, Lebouvier, Thibaud, Levy, Richard, Lippi, Anaïs, Mackowiak, Marie-Anne, Magnin, Eloi, Marelli, Cecilia, Martinaud, Olivier, Maureille, Aurelien, Migliaccio, Raffaella, Milongo-Rigal, Emilie, Mohr, Sophie, Mollion, Hélène, Morin, Alexandre, Nivelle, Julia, Noiray, Camille, Olivieri, Pauline, Paquet, Claire, Pariente, Jérémie, Pasquier, Florence, Perron, Alexandre, Philippi, Nathalie, Planche, Vincent, Pouclet-Courtemanche, Hélène, Rafiq, Marie, Rollin-Sillaire, Adeline, Roué-Jagot, Carole, Saracino, Dario, Sarazin, Marie, Sauvée, Mathilde, Sellal, François, Teichmann, Marc, Thauvin, Christel, Thomas, Quentin, Tisserand, Camille, Turpinat, Cédric, Van Damme, Laurène, Vercruysse, Olivier, Villain, Nicolas, Wagemann, Nathalie, Charbonnier, Camille, and Wallon, David

Abstract

To assess the likely pathogenic/pathogenic (LP/P) variants rates in Mendelian dementia genes and the moderate-to-strong risk factors rates in patients with Alzheimer disease (AD).

Published
2024
Full Text
View/download PDF

444. Prospective Associations Between Diffusion Tensor Imaging Parameters and Frailty in Older Adults.

Author

Maltais, Mathieu, Souto Barreto, Philipe, Perus, Lisa, Mangin, Jean‐François, Grigis, Antoine, Chupin, Marie, Bouyahia, Ali, Gabelle, Audrey, Delrieux, Julien, Rolland, Yves, Vellas, Bruno, Guyonnet, Sophie, Carrié, Isabelle, Brigitte, Lauréane, Faisant, Catherine, Lala, Françoise, Delrieu, Julien, Villars, Hélène, Combrouze, Emeline, and Badufle, Carole

Subjects
FRAIL elderly, DIFFUSION magnetic resonance imaging, BRAIN, ALZHEIMER'S disease, HEALTH risk assessment
Abstract

BACKGROUND: Cross‐sectional associations have been found between frail individuals and worse white matter (WM) integrity. However, the prospective association between WM integrity and frailty is still unclear. Our objectives were to measure associations between WM integrity using diffusion tensor imaging (DTI) and the 5‐year worsening of frailty in community‐dwelling older adults. DESIGN: Secondary analysis of the randomized controlled Multidomain Alzheimer Preventive Trial (MAPT). SETTING: Thirteen memory centers in France and Monaco between 2008 and 2011. PARTICIPANTS: Participants (mean age = 74.7 ± 3.9 years) with no dementia at baseline who had functional magnetic resonance imaging performed as part of the MAPT study (n = 227). MEASUREMENTS: Fractional anisotropy and mean diffusivity (MD), axial diffusivity (AxD), and radial diffusivity (RD) were acquired for 10 different brain regions. Frailty was assessed by the Fried frailty phenotype (score from 0 to 5, higher is worse) at up to seven time points for 5 years. Mixed effect ordinal logistic regression model was used to assess the prospective association between DTI parameters (independent variables) and frailty (dependent variable). All the analyses were adjusted for age, sex, baseline total intracranial volume, and the presence of one of the following cardiovascular risk factors (hypertension, diabetes, and/or hypercholesterolemia). RESULTS: A statistically significant association was found between the RD, AxD, and MD for different brain regions (anterior limb of internal capsule, external capsule, posterior corona radiata, posterior thalamic radiation, superior corona radiata, superior frontal occipital fasciculus, and superior longitudinal fasciculus) and worsening of frailty over 5 years after adjusting for multiple comparisons. CONCLUSIONS: This is the first study to show that WM integrity is associated with frailty in older adults. The mechanisms related to these results require further investigation. J Am Geriatr Soc 68:1050–1055, 2020 [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

445. Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides Aβ1–42 and Tau Proteins in Elderly Patients With Mild Cognitive Impairment

Author

Duron, Emmanuelle, primary, Vidal, Jean-Sébastien, additional, Grousselle, Dominique, additional, Gabelle, Audrey, additional, Lehmann, Sylvain, additional, Pasquier, Florence, additional, Bombois, Stéphanie, additional, Buée, Luc, additional, Allinquant, Bernadette, additional, Schraen-Maschke, Susanna, additional, Baret, Christiane, additional, Rigaud, Anne-Sophie, additional, Hanon, Olivier, additional, and Epelbaum, Jacques, additional

Published
2018
Full Text
View/download PDF

448. Alzheimer’s Disease: Advances in Drug Development

Author

Piton, Morgane, primary, Hirtz, Christophe, additional, Desmetz, Caroline, additional, Milhau, Jacqueline, additional, Lajoix, Anne Dominique, additional, Bennys, Karim, additional, Lehmann, Sylvain, additional, and Gabelle, Audrey, additional

Published
2018
Full Text
View/download PDF

449. Red blood cell membrane omega-3 fatty acid levels and physical performance: Cross-sectional data from the MAPT study

Author

Fougère, Bertrand, primary, de Souto Barreto, Philipe, additional, Goisser, Sabine, additional, Soriano, Gaëlle, additional, Guyonnet, Sophie, additional, Andrieu, Sandrine, additional, Vellas, Bruno, additional, Carrié, Isabelle, additional, Brigitte, Lauréane, additional, Faisant, Catherine, additional, Lala, Françoise, additional, Delrieu, Julien, additional, Villars, Hélène, additional, Combrouze, Emeline, additional, Badufle, Carole, additional, Zueras, Audrey, additional, Cantet, Christelle, additional, Morin, Christophe, additional, Van Kan, Gabor Abellan, additional, Dupuy, Charlotte, additional, Rolland, Yves, additional, Caillaud, Céline, additional, Ousset, Pierre-Jean, additional, Fougère, Bertrand, additional, Willis, Sherry, additional, Belleville, Sylvie, additional, Gilbert, Brigitte, additional, Fontaine, Francine, additional, Dartigues, Jean-François, additional, Marcet, Isabelle, additional, Delva, Fleur, additional, Foubert, Alexandra, additional, Marie-Noëlle-Cuffi, Sandrine Cerda, additional, Costes, Corinne, additional, Rouaud, Olivier, additional, Manckoundia, Patrick, additional, Quipourt, Valérie, additional, Marilier, Sophie, additional, Franon, Evelyne, additional, Bories, Lawrence, additional, Pader, Marie-Laure, additional, Basset, Marie-France, additional, Lapoujade, Bruno, additional, Faure, Valérie, additional, Yung Tong, Michael Li, additional, Malick-Loiseau, Christine, additional, Cazaban-Campistron, Evelyne, additional, Desclaux, Françoise, additional, Blatge, Colette, additional, Dantoine, Thierry, additional, Laubarie-Mouret, Cécile, additional, Saulnier, Isabelle, additional, Clément, Jean-Pierre, additional, Picat, Marie-Agnès, additional, Bernard-Bourzeix, Laurence, additional, Willebois, Stéphanie, additional, Désormais, Iléana, additional, Cardinaud, Noëlle, additional, Bonnefoy, Marc, additional, Livet, Pierre, additional, Rebaudet, Pascale, additional, Gédéon, Claire, additional, Burdet, Catherine, additional, Terracol, Flavien, additional, Pesce, Alain, additional, Roth, Stéphanie, additional, Chaillou, Sylvie, additional, Louchart, Sandrine, additional, Sudres, Kristel, additional, Lebrun, Nicolas, additional, Barro-Belaygues, Nadège, additional, Touchon, Jacques, additional, Bennys, Karim, additional, Gabelle, Audrey, additional, Romano, Aurélia, additional, Touati, Lynda, additional, Marelli, Cécilia, additional, Pays, Cécile, additional, Robert, Philippe, additional, Le Duff, Franck, additional, Gervais, Claire, additional, Gonfrier, Sébastien, additional, Gasnier, Yannick, additional, Bordes, Serge, additional, Begorre, Danièle, additional, Carpuat, Christian, additional, Khales, Khaled, additional, Lefebvre, Jean-François, additional, El Idrissi, Samira Misbah, additional, Skolil, Pierre, additional, Salles, Jean-Pierre, additional, Dufouil, Carole, additional, Lehéricy, Stéphane, additional, Chupin, Marie, additional, Mangin, Jean-François, additional, Bouhayia, Ali, additional, Allard, Michèle, additional, Ricolfi, Frédéric, additional, Dubois, Dominique, additional, Bonceour Martel, Marie Paule, additional, Cotton, François, additional, Bonafé, Alain, additional, Chanalet, Stéphane, additional, Hugon, Françoise, additional, Bonneville, Fabrice, additional, Cognard, Christophe, additional, Chollet, François, additional, Payoux, Pierre, additional, Voisin, Thierry, additional, Peiffer, Sophie, additional, Hitzel, Anne, additional, Zanca, Michel, additional, Monteil, Jacques, additional, Darcourt, Jacques, additional, Molinier, Laurent, additional, Derumeaux, Hélène, additional, Costa, Nadège, additional, Vincent, Christian, additional, Perret, Bertrand, additional, Vinel, Claire, additional, and Olivier-Abbal, Pascale, additional

Published
2018
Full Text
View/download PDF

450. ADDIA, A MULTICENTER CLINICAL STUDY OF PROOF-OF-PERFORMANCE TO VALIDATE BLOOD-BASED BIOMARKERS FOR THE DIAGNOSIS OF ALZHEIMER’S DISEASE (AD): THE STUDY PROTOCOL

Author

Dubois, Bruno, primary, Bier, Jean-Christophe, additional, Blanc, Frederic, additional, David, Renaud, additional, Démonet, Jean-François, additional, Firat, Hüseyin, additional, Frisoni, Giovanni B., additional, Gabelle, Audrey, additional, Gurvit, Hakan I., additional, Ivanoiu, Adrian, additional, Magnin, Eloi, additional, Marizzoni, Moira, additional, Moussaoui, Saliha, additional, Pasquier, Florence, additional, and Sellal, François, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results